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Abstract of thesis entitled: 
Identification of novel candidate tumor suppressor genes at 5q and 14q for 
multiple carcinomas by integrative genomics and epigenetics 
Submitted by NG, Ka Man 
for the degree of Master of Philosophy 
at The Chinese University of Hong Kong in August 2007 
Cancer is an important cause of death worldwide. However, the trend of cancer 
mortality generally has not shown any marked decrease over the years. There is a 
need to develop effective diagnostic and therapeutic agents for cancer but this is 
limited by the current knowledge on carcinogenesis. Carcinogenesis is a complex 
and stepwise process with the accumulation of multiple genetic and epigenetic 
changes, resulting in aberrant activation of oncogenes and/or inactivation of tumor 
suppressor genes (TSGs). Since the current list of TSGs is limited, identification of 
novel TSGs will lead to better understanding the molecular pathogenesis of cancer. 
Nasopharyngeal carcinoma (NPC), which is a prevalent malignancy in Hong 
Kong, was used as a cancer model for the identification of novel TSGs. 
Chromosomal loci with frequent losses can flag regions likely to harbor TSGs. 1-Mb 
array-CGH was performed previously to detect genome-wide DNA copy number 
aberrations in a panel of NPC cell lines, and from which 5ql l -q l2 and 14q32 were 
found to have frequent copy loss. Previous studies also reported that these two 
regions demonstrated frequent abnormalities in multiple cancers, further supporting 
the presence of TSGs. But up to date, there are limited TSGs being characterized at 
these regions. Notewoilhily, apart from genetic aberrations, epigenetic changes such 
as DNA methylation are now recognized as a common mechanism for the 
inactivation of TSG during carcinogenesis. In this regard, the objective of this project 
was to identify novel epigenetically silenced candidate TSGs in these two regions 
through an integrative genomic and epigenetic approach. 
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DitYerential expression profiling of all the candidate genes residing in these 
two putative TSG loci was first performed in a panel of NPC cell lines and normal 
upper respiratory tract tissues by semi-quantitative RT-PCR. A number of down-
regulated genes were identified, with three candidates (MGC80 and TUSC14 at 5ql2, 
and DLKl at 14q32) selected for further analysis. MGC80 and TUSC14 were found 
to be frequently down-regulated in multiple carcinoma cell lines, including 
esophageal, hepatocellular, lung, breast, gastric, colorectal and renal cell carcinomas. 
As revealed by methylation-specific PCR (MSP) and bisulfite genomic sequencing 
(BGS), CpG methylation of MGC80 md TUSC14 promoters was frequently detected 
in multiple carcinoma cell lines, but not in any non-tumor cell line. An inverse 
correlation between methylation status and expression for these two genes was well 
detected in various carcinomas. The expression of MGC80 and TUSC14 was restored 
upon pharmacologic or genetic demethylation, suggesting that DNA methylation is 
directly implicated in their silencing. Further functional studies revealed that ectopic 
expression of MGC80 or TUSC14 could strongly suppress the anchorage-dependent 
and -independent growth of multiple tumour cells lacking the expression, supporting 
MGC80 and TUSC14 as functional TSGs. Similarly, the paternal imprinted gene 
DLKl at 14q32 was identified as a candidate TSG frequently silenced by methylation 
in NPC, and its silencing was found to be associated with gain of methylation of a 
regulatory region upstream of MEGS. 
In conclusion, three epigenetically silenced candidate TSGs, MGC80, 
TUSC14 and DLKl, were identified in this study. Not only can the novel findings 
presented in this study help to unveil the molecular basis of carcinogenesis, but the 
candidate TSGs can also serve as a promising avenue for the development of non-
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Chapter 1 Literature review 
For the past decades, cancer has been the leading cause of death worldwide 
and it has emerged as a major health problem in Hong Kong. In 2004, more than 
10,000 people died of different forms of neoplasm, altogether accounting for over 
30% of all deaths (Hong Kong Health Authority Report 2004). This also represented 
an increase of over 20% when compared with the number of cancer deaths in 1993. 
Among the top cancer killers, lung carcinoma remains as the leading cancer killer for 
both genders in 2004, other major causes of cancer deaths include liver, colorectal, 
stomach, breast, nasopharyngeal and esophageal carcinomas and non-Hodgkins's 
lymphomas. Notably, the trend of cancer mortality shows no significant sign of 
decrease over the years. Such a high mortality rate is largely attributed to poor 
diagnosis at early stage and lack of effective therapeutic targets. Indeed, the 
pathogenesis of human cancers is a multi-step and complex process, which involves 
a series of genetic alterations including aberrant activation of proto-oncogenes and 
the inactivation of tumor suppressor genes (TSGs). The elucidation of carcinogenesis 
necessitates the identification of all the cancer-related genes. In the current project, 
the main focus was the identification of novel TSGs, since the current list of well-
identified TSGs is limited. Undoubtedly, elucidation of novel TSGs will help to 
bridge the gaps in the understanding of carcinogenesis and provide powerful insights 
into the diagnosis and treatment of cancer. 
1.1 Tumor suppressor genes (TSGs) and the modes of TSG inactivation during 
carcinogenesis 
As mentioned above, cancers arise as a result of an accumulation of inherited 
and somatic mutations, a concept accentuated by the demonstration that cellular 
oncogenes, when deregulated mutationally, lead to tumor formation (Stehelin et al. 
1976). The discovery of abnormally activated oncogenes during carcinogenesis 
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fueled the idea of the presence of a distinct class of ‘anti-oncogenes’ or now so-
called tumor suppressor genes (TSGs), which act to oppose their effect and/or 
possess the ability to suppress tumor formation. It is now generally accepted that 
TSGs encode for proteins that function in growth regulatory or differentiation 
pathways, and regulate the cell cycle negatively. Notably, loss of their function 
contributes to tumor initiation and progression. The presence of TSGs was first 
demonstrated in experiments involving somatic cell fusion and chromosome 
segregation, which showed the existence of genes could suppress tumorigenicity 
(Stanbridge 1976). The inactivation of TSGs during carcinogenesis generally follows 
the ‘two-hit’ hypothesis, which was proposed by Alfred Knudson in 1971 based on 
the study of Rb gene in inherited and non-inherited form of retinoblastoma. 
According to the classical ‘two-hit’ model, loss of TSG function only occurs when 
both alleles are inactivated genetically. That is, a germline mutation of one allele 
predisposes to tumor formation; next the remaining normal allele is inactivated by 
somatic mutation or loss of heterozygosity (LOH) acquired during lifetime, resulting 
in tumor initiation (Knudson 1993; Knudson 2001). This model led to the discovery 
of a whole generation of tumor suppressors such as the well-characterized 
retinoblastoma protein, Rb, and p53 (Sherr 2004). Nowadays, one of the promising 
ways of identifying a tumor suppressor (TS) locus is by loss of heterozygosity (LOH) 
study in specific human cancers. Even though LOH on different chromosome regions 
is often observed in human cancers, the task of identifying novel TSGs has proven 
difficult and the rate is substantially low. It is probably due to the fact that many 
TSGs take alternative paths to inactivation (Baylin and Herman 2000; Jones and 
Baylin 2002). We now know that epigenetic modifications such as promoter 
hypermethylation can silence TSGs, either on both alleles or on just one copy when 
the other is lost (Jones and Laird 1999). In this regard, the ‘two-hit’ model is now 
further extended to the involvement of epigenetic aberrations that can act as one of 
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the hits in concert with LOH or as both hits in the inactivation of TSG during 
tumorigenesis (Fig.1-1). 
Figure 1. 
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Figure 1-1. Different paths of TSG inactivation during carcinogenesis, a & b, 
The classical Knudson's two-hit model involves an initial mutational event that leads 
to gene inactivation during tumor development. LOH or deletion results in the 
functional inactivation of both alleles, c & d, The mutational event can be followed 
by gene silencing through promoter methylation without LOH. d. Both gene copies 
without LOH or gene mutation are inactivated by epigenetic silencing, e & f, 
Haploinsufficient tumor-suppressor genes do not need to lose both functional copies 
to confer increased risk. Loss of a single gene copy may occur by mutation, deletion 
or silencing, and the other functional allele may be retained (Modified from (Balmain 
et al. 2003) 
1.2 Epigenetic modifications 
Although the genetic information of the human genome has long been 
regarded as the blueprint for the manufacture of all the proteins, it is apparent that 
there are other heritable factors that can also determine gene expression, which in 
turn control the structure and functions of the cell. These heritable factors are termed 
'epigenetic modifications', which refer to any heritable changes that can regulate 
gene expression but do not involve a change in the primary nucleotide sequence 
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(Jones and Baylin 2002). The study of epigenetic modifications has been the 
‘hotspot，in cancer research in recent years. It is because epigenetic changes such as 
aberrant DNA methylation and histone modifications are implicated in virtually all 
types of human neoplasms. Epigenetic modifications have been shown to play 
critical roles in regulation of gene expression, chromosome instability, genomic 
imprinting and X-chromosome inactivation (Li 2002). Detail discussion will be made 
on the participation of epigenetic aberrations during carcinogenesis in the following 
sessions, particularly on the role of aberrant DNA methylation in the deregulation of 
TSGs expression, which is the main focus of this project. 
1.2.1 DNA methylation 
In normal mammalian genome, DNA methylation is the only known natural 
modification of DNA; it refers to the addition of a methyl group at C5 of the 
cytosines in the CpG dinucleotide (Baylin and Herman 2000). This modification is 
maintained by a number of DNA methyltransferases (DNMTs) and plays critical 
roles in the human genome such as in defense against viral sequences and in 
transcriptional repression of genes (Bird 2002). The occurrence of CpG in 
mammalian genomes is lower than the expected frequency (1/16 or �6o/o) and the 
CpG dinucleotides are progressively depleted from the genome over evolution. Over 
70% CpG sites are highly methylated throughout the human genome (Ehrlich et al. 
1982). By contrast, short regions of DNA (0.5 to several kb) with the expected or 
even higher frequency of CpGs, also known as CpG islands, are normally kept free 
of methylation, with the exception of CpG island on the inactive X chromosome in 
females. CpG islands are located in the proximal promoter region of about 40-50% 
of human genes and, when methylated, can cause stable heritable transcriptional 
silencing. Aberrant methylation of CpG island is found in early carcinogenesis, and 
is now regarded as a hallmark of human cancers (Jones and Baylin 2002). In contrast 
to DNA hypermethylation, genome-wide hypomethylation has also been linked to a 
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number of mechanisms that can drive cancer progression (Wilson et al. 2007). 
Nonetheless, genomic imprinting, a variant of DNA methylation that causes mono-
allelic expression of imprinted genes, is noteworthy in carcinogenesis, as loss of 
imprinting (LOI) leading to deregulated gene expression is frequently found in a 
wide range of human tumors (Jelinic and Shaw 2007). 
1,2. la Establishment of DNA methylation patterns and DNA methyltransferases 
DNA methylation is tightly regulated. DNA methylation patterns are reset 
early in embryogenesis by undefined regulatory mechanisms, and re-established 
early during development. After that, the patterns are stably transmitted to the next 
generation during cell division. The establishment of DNA methylation pattern is 
assisted and maintained by several DNMTs (DNMTl, DNMT3A, DNMT3B and 
DNMT3L). DNMTs catalyze the transfer of a methyl group from S-
adenosylmethionine to the C5 of a cytosine in the CpG. DNMTl, the best studied 
methyltransferase in the family, has a primary role in maintaining DNA methylation 
patterns after replication of a methylated sequence (Ehrlich et al. 1982). On the other 
hand, DNMT3A and DNMT3B are responsible for the de novo methylation of DNA. 
DNMT3L, however, does not possess intrinsic DNA methyltransferase activity 
(Klose and Bird 2006); it serves to modulate the activity of DNMT3A and DNMT3B 
(Chedin et al. 2002; Chen et al. 2005; Suetake et al. 2004), and positively regulate 
the establishment of DNA methylation at imprinted regions and repetitive sequences 
(Bourc'his et al. 2001; Arima et al. 2006). They are found to be highly expressed in 
undifferentiated stem cells but present at low levels in somatic tissues (Okano et al. 
1999) and are proposed to have a role in methylation of repetitive sequence. It was 
demonstrated that mice embryo lacking both copies of either DNMTl or DNMT3A 
die before birth, and mice lacking DNMT3B die few weeks after birth (Okano et al. 
1999), high-lightmg the vital role of DNMTs. 
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1.2,1 b DNA hypermethylation and carcinogenesis 
Given the ability of epigenetic modifications in regulating gene expression, 
there should be no doubt that cancer cells utilize aberrant DNA methylation on their 
genome to alter gene expression patterns that favor their growth. DNA 
hypermethylation at CpG islands, especially at those associated with regulatory 
promoters, is now regarded as a critical event in cancer development and has 
received extensive investigation in silencing of TSGs in recent years. However, it 
remains obscure whether methylation is a primary silencing event or a secondary one 
that is triggered by earlier chromatin-remodeling events during carcinogenesis. 
Although this appears as a ‘chicken-and-egg’ question at the moment, it seems that 
promoter methylation must be integral to loss of gene function as drugs that can 
cause demethylation, such as 5-aza-2'deoxycytidine (5-Aza-CdR), are able to 
reactivate the expression of silenced genes in cancer cells (Jones and Taylor 1980; 
Jones and Baylin 2002; Egger et al. 2004). 
1,2.1c Mechanism for gene silencing by CpG methylation 
Although much work remain to elucidate the association between gene 
silencing and aberrant CpG methylation in cancers, hypermethylated promoters 
demonstrate certain features that are typical of pericentrometric heterochromatin (Fig. 
1-2), whose conformation does not favor transcription. The CpG islands associated 
with gene promoters are unmethylated in normal cells, regardless of whether the 
gene is actively transcribed or not (Baylin and Herman 2000). These CpG islands 
reside, especially in active promoters, in chromatin that is composed of widely and 
irregularly spaced nucleosomes, which are associated with highly acetylated histones. 
However, the CpG sites residing in the gene body other than the CpG island are 
generally highly methylated and demonstrate CpG depletion. The unmethylated CpG 
sites around the transcription start site are protected from DNMTs and 
transcriptionally repressive complexes that contain histone de-acetylases (HDACs) 
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and co-repressor proteins. This makes the chromatin conformation favorable for 
transcription. It is noteworthy that these CpG islands remain unmethylated when the 
associated gene is transcriptionally inactive, if required by normal cellular settings 
(Jones and Baylin 2002; Jones and Baylin 2007). 
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Figure 1-2. The configuration of a transcriptionally active gene promoter 
associated with an unmethylated CpG-island. The promoter is unmethylated, and 
transcriptionally active. The CpG island is protected from methylation, whereas the 
areas immediately downstream show CpG depletion and heavy methylation typical 
for most of the genome. The chromatin constitution of the island is transcriptionally 
favorable and characterized by widely spaced and non-compacted nucleosomes. The 
promoter is fully accessible to a typical transcription complex composed of histone 
acetylase (HAT), co-activator (CA), and basal transcription factors (TF) but does not 
interact with DNA methyltransferases (DNMTs). (Modified from Baylin and 
Herman 2000; Jones and Baylin 2002) 
Certain CpG island-containing promoters of TSGs are hypermethylated 
during carcinogenesis, which result in transcriptional inactivation of the critical 
TSGs. The loss of transcription is likely to involve the integration of DNA 
methylation with chromatin organization and the acetylation of histones and other 
proteins (Fig. 1-3). The critical link between methylation and transcriptionally 
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repressive chromatin is through the methyl-cytosine-binding proteins (MBPs), which 
reside in complexes containing active HDACs such as the HDACl and/or HDAC2 
(Nan et al. 1998). At least two separate complexes have been identified, one 
involving the methyl-CpG-binding protein 2 (MECP2; Jones et al. 1998; Nan et al. 
1998), and another involving methyl-CpG-binding-domain proteins MBDl and 
MBD2 (Jin et al. 2005; Ng et al. 1999). In particular, these MBPs have been shown 
to act as transcriptional repressors, which are associated with co-repressor, such as 
SIN3, which can directly bind HDACs (Nan et al. 1998; Ng et al. 1999). Collectively, 
the recruitment of HDACs by binding of MBPs to the aberrantly hypermethylated 
promoter may present a repressive chromatin conformation, which in turn lead to 
gene silencing through the deacetylation of histories and other proteins. This also 
provides a clue for the paradox that whether DNA methylation is a primary event 
that may initiate the transcriptional repression during carcinogenesis. 
From the interaction between DNA methylation and HDAC activity in 
maintaining the aberrantly silencing of hypermethylated genes in cancers, it seems 
that DNA methylation is the dominant event that seals gene repression (Jones and 
Baylin 2002). This conception is accentuated by the finding that inhibition of HDAC 
activity alone, by specific inhibitors such as Trichostatin A (TSA), cannot reactivate 
the expression of the aberrantly hypermethylated and silenced genes in cancer cells 
(Cameron et al. 1999). However, TSA can acutely reactivate the expression of the 
methylated gene if the cells were pre-treated with demethylating drugs, such as 5-
Aza-CR, which can demethylate the CpG island involved (Cameron et al. 1999). 
On the other hand, it has been proposed that most transcribed genes are 
normally occupied both by activating and repressing complexes simultaneously. The 
expression level is thus determined by the relative amount of these complexes on the 
promoter and the post-translational modifications such as acetylation of histone and 
other proteins involved. In case of the aberrantly methylated promoters in cancer 
cells, the way of gene repression can be viewed as the exclusion of activating 
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complexes with acetylase activity and the recruitment of transcriptional repressors 
and histone deacetylases, both by the dense methylation at promoter CpG island 
(Baylin and Herman 2000). 
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Figure 1-3. The configuration of a transcriptionally inactive gene promoter 
associated with an aberrantly methylated CpG-island. The gene is aberrantly 
methylated, and transcriptionally silenced during carcinogenesis. The CpG island is 
heavy methylated, fully accessible to DNMTs, and the nucleosomes contain 
deacetylated histories and are more evenly spaced and more compacted. The 
methylated CpGs in the island interact with MBP-HDAC complexes and the 
transcriptional activator complex is excluded from the region. (Modified from Baylin 
and Herman 2000; Jones and Baylin 2002) 
In addition to genetic abnormalities such as mutations and deletions, DNA 
hypermethylation has been regarded as a common mechanism for the inactivation of 
TSGs. Ever since the demonstration of inactivation of the tumor suppressor Rb by 
promoter hypermethylation in retinoblastoma (Greger et al. 1989), many more new 
members have been identified and added to the list of TSGs that are frequently 
inactivated epigenetically, such as 价似义 VHL, CDHl and MLHl. In particular, 
the mode of MLHl inactivation presents an excellent example to illustrate the 
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importance of epigenetic silencing in cancer. The promoter methylation of MLHl 
have been observed in the normal colon epithelium of patients that have colorectal 
cancer with microsatellite instability, demonstrating that epigenetic changes can 
predispose to mutation events during tumor progression (Nakagawa et al. 2001; 
Esteller et al. 1999a). Another example is the MGMT inactivation in colorectal 
cancer in which promoter hypermethylation seems to precede genetic changes in pre-
malignant polyps that do not harbor mutations yet (Esteller et al. 2000; Esteller et al. 
1999b; Qi et al. 2005). 
1.23d DNA hypomethylation and carcinogenesis 
Loss of DNA methylation at CpG dinucleotides was indeed the first 
epigenetic aberration to be identified in cancer cells. Global and regional DNA 
hypomethylation are also hallmarks of cancer development and received a great deal 
of attention in cancer research (Feinberg and Vogelstein 1983; Goelz et al. 1985; 
Wilson et al. 2007). But the scene was then shifted to the role of hypermethylation in 
carcinogenesis, because many cancer-related genes, TSGs in particular, are 
deregulated by regional hypermethylation. Hypomethylation refers to the progressive 
and global decrease in the number of cytosine bases that had been methylated to 
form 5-methylcytosines. It is typical in virtually all both benign and malignant forms 
of neoplasms, and is frequently linked with alterations in chromatin structure, 
changes in DNMTs and LOI (discussed below; Matsuzaki et al. 2005; Holm et al. 
2005). This results in chromosomal instability and aberrant gene activation that could 
drive onset and progression of cancer, as well as other diseases (Wilson et al. 2007). 
Hypomethylation in cancer cells is particularly severe in the repetitive 
sequences residing in satellite or pericentrometric regions (Ehrlich et al. 2003; Qu et 
al. 1999a), which may make chromosomes more susceptible to breakage, and thus 
result in genomic instability. It plays critical role in several cancers frequently 
contain unbalanced chromosomal translocations with breakpoints in pericentrometric 
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DNA of chromosome 1 and 16 (Qu et al. 1999b). It has been recently demonstrated 
that hypomethylation on satellite regions may participate in the development and 
progression of urothelial carcinomas by inducing LOH on chromosome 9 (Nakagawa 
et al. 2005). Hypomethylation can also lead to reactivation of previously silenced 
retrotransposons, which may in turn lead to disruption of normal gene structure and 
function (Suter et al. 2004). Besides, DNA hypomethylation can lead to reactivation 
of oncogenes and/or cancer-related genes. It has been reported that the S100A4 
metastasis-associated gene in colorectal carcinoma (Nakamura and Takenaga 1998), 
cyclin D2 and Mas pin gene in gastric carcinoma are aberrantly reactivated by 
demethylation occurring at the promoter region, which disrupts gene repression in 
specific type of cancers (Oshimo et al. 2003; Akiyama et al. 2003). Despite the 
significance of hypomethylation in genomic instability and deregulation of gene 
expression in cancer, the role of hypomethylation in immune function has also been 
extensively investigated. In a number of cancers, the cancer/testis antigens (CTA), 
whose expression are normally restricted to testes, are found to be hypomethylated 
and expressed, and are immunogenic in cancer patients (Scanlan et al. 2004). 
1.2,1 e Loss of imprinting and carcinogenesis 
Genomic imprinting refers to the conditioning of the maternal and paternal 
genomes during gametogenesis, such that the gene expression is exclusively 
restricted to a specific parental allele in the offspring (Surani et al. 1984). It is an 
epigenetic phenomenon resulting from DNA methylation or modification of 
protruding histones, which marks the imprinted status of a particular regulatory 
region governing the expression of the associated gene. Indeed, the methylation is 
established during gonad development, and preserved through cell division. The 
human imprinted genes were first discovered following from studies of the same 
genes pair, IGF2 and H19, in mouse. IGF2 and H19 were found to be expressed 
exclusively from the paternal and maternal allele, respectively (Zhang and Tycko 
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1992; Giannoukakis et al. 1993). The study of mechanism of imprinting has now 
became another focal point in cancer epigenetics, ever since the demonstration of the 
direct role of DNA methylation in maintaining allele-specific gene expression (Li et 
al. 1993). 
The role of imprinting has been emphasized in embryonic development; it 
assures that the proteins encoded by imprinted genes that are critical to embryonic 
growth, placental growth and adult metabolism, are expressed at correct levels 
(Vilkaitis et al. 2005). On the other hand, loss of imprinting (LOI), which leads to 
deregulation of the imprinted genes, has also been suggested to play a critical role in 
the onset and progression of a wide variety of human tumors (Jelinic and Shaw 2007). 
That is, LOI in cancer involves reactivation of the normally silent allele of a growth-
promoting gene, and/or silencing of the normally active allele of a TSG. The best 
example to illustrate this phenomenon is the LOI at IGF2/H19 imprinted region as a 
result of hypermethylation at the differentially methylated region (DMR), which in 
turn leads to biallelic expression of the growth-promoting gene IGF2 in Wilms 
tumors and other tumors (Rainier et al. 1993; el-Naggar et al. 1999). Similar 
hypermethylation event can also be seen with the putative TSG ARHl in follicular 
thyroid carcinoma (Weber et al. 2005). However, the popular LOI mechanism for 
IGF2/H19 does not apply to colorectal cancer, in which LOI is caused by 
hypomethylation at DMR of IGF2 (Cui et al. 2002), indicating that LOI can be 
attributed to either hypermethylation or hypomethylation at critical DMR. 
1.2. If Potential factors leading to aberrant methylation patterns in cancers 
As mentioned earlier, the DNA methylation pattern in cells is assisted and 
maintained by the DNMTs, so one may think that any changes in the DNA 
methylation pattern is related to the deregulation of these DNMTs during 
carcinogenesis. That may be the case, but not all. The potential contribution of these 
enzymes to the aberrant methylation patterns in cancer is more complex than we 
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once thought, and inconsistent data have been seen with the deregulation of DNMTs 
in different types of cancers. In addition to focal hypermethylation at promoters, 
cancers often simultaneously demonstrate genome-wide hypomethylation (Wilson et 
al. 2007), and modest elevation in expression of all three DNMT genes (Robertson et 
al. 1999). Argument thus arises as to whether these increases reflect increased 
proliferative activity that is inherent to tumor cells. It has been demonstrated that the 
expression level of DNMTl correlate with cellular proliferative rate in certain types 
of cancers (Baylin and Herman 2000). Recent studies, however, demonstrated that 
the progressive increase in expression of DNMTl in cancers is not entirely a 
secondary result of increased cell proliferative activity, but is associated with other 
factors during carcinogenesis (Sawada et al. 2006). Also, in certain in vivo 
experiments, genetic or antisense reductions of DNMTl block cellular 
transformation and tumorigenesis (Laird et al. 1995; MacLeod and Szyf 1995), 
demonstrating the pivotal role of DNMTl. However, neither DNMTl nor DNMT3 
expression was found to relate to changes in methylation patterns in colorectal cancer 
(Eads et al. 1999). Furthermore, there is no evidence for a link between DNMTl and 
DNMT3B levels and global hypomethylation in any human cancers studied so far 
(Wilson et al. 2007). 
The mechanism for the aberrant methylation patterns in cancers is still 
obscure, and thus warrants further elucidation. Nevertheless, histone modifications 
and chromatin remodeling (discussed below), which intricately involved with DNA 
methylation during the establishment of methylation patterns and gene 
hypermethylation, are also critical to the studies of aberrant methylation in 
carcinogenesis. Our bias also seems to lie on the hypothesis that any changes in 
DNMT activity in many tumor types is permissive to aberrant methylation, yet we 
should also keep in mind that there may be other even more critical factors working 
in concert with DNMTs to bring about hypo- and hypermethylation. 
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1.2.2 Deregulation of histone modifications and carcinogenesis 
In addition to the study of DNA methylation, considerable attention is now 
being given to histone modifications, but the current knowledge is less advanced in 
comparison. DNA is wrapped around an octameric nucleosome core consisting of 
two histone 2A and histone 2B dimmers (H2A-H2B), and a histone 3 (H3) and 
histone 4 (H4) tetramer. Histories are basic proteins that consist of a globular domain 
and a histone tail that protrudes out of the nucleosomes. These histone tails are 
targets for post-translational covalent modifications, including methylation, 
acetylation, phosphorylation and citrullination. Combinations of modifications are 
thought to constitute a ‘histone code'. There is increasing evidence that 
modifications of histone codes act in diverse biological processes such as gene 
regulation, DNA repair and chromosome condensation (Jenuwein and Allis 2001). 
Histone modifications are important in chromatin remodeling and gene 
activation. Hypoacetylation of H3 and H4 are associated with heterochromatic, 
transcriptionally inactive regions in the genome. The states of acetylation and 
deacetylation are regulated by histone acetyltransferases (HAT) and deacetylases 
(HDAC) and recognised by effector protein containing a bromodomain (Dhalluin et 
al. 1999). Apart from this, methylation at lysine residues Lys4 and Lys9 of H3 (H3-
K4 & H3-K9) has been described (Strahl et al. 1999; Peters et al. 2002). It is widely 
accepted that aberrant methylation of TSGs is accompanied by two key 
modifications at H3-K9, namely deacetylation and methylation. Acetylation of H3-
K9 correlates with active chromatin and gene expression, whereas methylation of 
H3-K9 is associated with gene silencing by recruiting heterochromatin-associated 
proteins (Peters et al. 2002). It is also noteworthy that H3-K4 has been correlated 
with active gene expression (Strahl et al. 1999). Since methylation at histone code 
has been associated with active gene expression, a histone methyltransferase SMYD3 
has been suggested to potentially promote transcription of oncogenes and play a role 
in proliferation of cancer cells (Hamamoto et al. 2004). Also, loss of 
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monoacetylation of H4-K16 and trimethylation of H4-K20 have been demonstrated 
in human cancers recently and these modifications have been proposed as hallmarks 
for malignant transformation (Fraga et al. 2005). In case of hypomethylation, specific 
loss of association of the histone acetyltransferase MOF, MOZ and MORF with 
D4Z4, Sat2 and NBL2 repeat sequences, respectively, was observed (Wilson et al. 
2007). Collectively, disruption of chromatin structure and histone modification 
contributes greatly to cancer development, and could have downstream effects on 
DNA methylation patterns as well as aberrant gene regulation. It is also anticipated 
that more critical factors involving in histone modifications will be elucidated. 
1.2.3 Interplay between chromatin modifications and DNA methylation 
Despite the fact that the scenario of DNA methylation in gene regulation is 
becoming more unambiguous, little is known about the regulation of DNA 
methylation, which may even be more critical. Recent discoveries have begun to link 
histone codes to the targeting of methylation to DNA. DNA methylation is tied to 
modifications in the chromatin and methylated DNA present as a target for 
transcriptional repressor complexes, including methyl-binding proteins and HDACs, 
as discussed above. Recent data obtained from two model organisms, Arabidopsis 
thaliana and Neurospora crass a, have provided an important clue to the link between 
specific histone code and DNA methylation (Jackson et al. 2002; Vongs et al, 1993). 
In A. thaliana, one mutant ddml {decreased in methylation), which is defective in 
DNA methylation, showed only 30% of the normal DNA methylation level in 
repetitive elements. Ddml is a member of the SNF2-like helicase superfamily, a 
group of proteins that are able to disrupt interaction between histories and DNA 
(Jeddeloh et al. 1999). This suggested that chromatin remodelling is prerequisite for 
the access of DNMTs to DNA sequences to be methylated. 
On the other hand, one mutant strain of N. crassa was characterized recently 
to provide further lines of evidence that link histone codes and DNA methylation 
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(Tarnaril and Selker 2001). The mutant dim-5, which was isolated in a selection 
experiment for strains resistant to 5-Aza-CR, demonstrated reduced DNA 
methylation, and exhibited slow and irregular growth. Mutation in the gene dim-5 
identified in this mutant was found to be responsible for such a phenotype. Isolation 
and characterization of this gene identified it as a protein containing a SET domain, 
which is characteristic for histone methyltransferases. Also, a recent study has 
identified a methyltransferase gene KRYPTONITE, which is specific to H3-K9. 
Loss-of-function of KRYPTONITE resemble mutants in the DNA methyltransferase 
gene chromomethylase 3 (CMT3), showing that loss of cytosine methylation at sites 
of CpNpG trinucleotides and reactivation of endogenous retrotransposon sequences 
in A. t ha liana (Jackson et al. 2002). This study also demonstrated that DNA 
methylation is controlled by H3-K9 methylation, through interaction of CMT3 with 
methylated histones. Furthermore, they showed that mutating the histone H3 gene at 
the sequence coding for lysine 9 caused loss of in vivo DNA methylation. In a more 
recent study, it was suggested that trimethylated H3 Lys9, which is methylated by 
DIM-5, marks chromatin regions for cytosine methylation instead of dimethylated 
H3-K9 (Tamaru et al. 2003). These finding are important as they indicate that 
methylation of H3-K9 might somehow be required for establishment of DNA 
methylation, although it is not to date in humans. It is proposed that H3-K9 
methylation might bring about the binding of DNMTs to the methylated lysine or to 
the key proteins that are required for histone methylation, such as Hp la or histone 
methyltransferases (HMTs) themselves. Interesting, some HMTs contain MBP-like 
domain, which indicate that additional interaction may exist between the histone and 
the DNA methylation process (Zhang and Reinberg 2001). Unquestionably, further 
study is needed to prove whether such phenomenon exists in mammalian systems. 
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1.3 Identification of tumor suppressor genes (TSGs) 
The typical strategy to identify novel TSGs in cancers is often based on the 
classical feature of a tumor suppressor. That is, the function of tumor suppressor is 
lost in cancer cells, which occurs when both copies of the gene are inactivated 
genetically. It can be viewed as a mutation is first disposed to one of the allele during 
cancer development, followed by LOH occurring in a large part of chromosome 
containing the remaining allele. In this regard, the identification of TSGs often 
begins with the characterization of a frequently deleted region in a particular tumor; 
and hunt for genes harbouring inactivating mutations in the corresponding region of 
the undamaged chromosome. This has led to the discovery of a number of classical 
TSGs, including the Rb and p53. However, the identification of TSGs by such means 
has been proven difficult and slow. Also, in most of the cases, the hunt for genetic 
mutations leading to gene silencing may not be feasible, due to the fact that cancer 
cells can adopt other tactics to inactivate those genes that impede rapid cell growth. It 
has been proven that cancer cells use epigenetic mechanisms, perhaps in a more 
frequent manner, to silence the TSGs (Balmain 2002). Indeed, there are LOH regions 
in which epigenetic aberration is the dominant event to define the critical genes. One 
example is the RASSFIA at 3p21 (a region demonstrates frequent LOH in multiple 
carcinomas), which shows frequent promoter methylation in multiple tumors but the 
involvement of genetic alterations is rare (Dammann et al. 2000). This type of TSGs 
is now termed Class II TSGs (Balmain 2002; Sager 1997). Nevertheless, 
characterization of the frequently deleted regions remains useful to guide searches 
for TSGs as one can take epigenetic silencing into account during the elucidation of 
critical genes within the region of interest. 
Based on genome-wide screening of differentially methylated regions 
between normal and tumor cells, several techniques have been emerged to identify 
epigenetically silenced TSGs, such as RLGS (restriction landmark genomic 
scanning), MS-RDA (methylation sensitive-representational difference analysis) and 
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CGI array (Ushijima 2005). For instance, RGLS revealed that a candidate TSG, 
SOCSl, was frequently inactivated by methylation in hepatocellular carcinoma 
(Yoshikawa et al. 2001). By combining MS-RDA and aCGH to detect for methylated 
sequences in NPC and genome-wide copy number aberrations, respectively, a 
protocadherin gene PCDHIO was recently identified as a novel candidate TSG in 
NPC and other carcinomas (Ying et al. 2006). cDNA-microarray analysis combined 
with 5-aza-CR treatment of a colon cancer cell line demonstrated that SFRPl, a 
negative regulator of WNT-signalling pathway, was silenced in colon cancers 
(Suzuki et al. 2004). Regardless of how the TSGs are being identified, an important 
final step is the functional characterization of the bona fide TSGs. 
Although the participation of epigenetic modifications in gene silencing will 
make the identification of novel TSGs much more complicated, those epigenetically 
silenced TSGs may present as good therapeutic targets as they are not mutated, and 
could be reactivated by drugs that can alter or reverse DNA methylation. 
1.4 Nasopharyngeal carcinoma as a cancer model of the current project 
Nasopharyngeal carcinoma (NPC) is a distinctive type of head and neck 
cancer. It is a squamous carcinoma that occurs in the epithelial lining of the 
nasopharynx. Intriguingly, NPC draws a great deal of attention in cancer research, 
despite the fact that it is a rare malignancy worldwide. The major reason is that it 
shows a remarkable geographic and racial distribution. NPC has an unusual high 
incidence rate of -25-30 per 100,000 persons among Southern Chinese, in contrast 
with the low incidence rate well under 1 per 100,000 per persons for both sexes in 
Caucasians from North America and other Western countries. This dramatic 
difference in the incidence among populations and geographic areas strongly 
suggests the involvement of genetic susceptibility and environmental factors in NPC 
development (Wei and Sham 2005; Tao and Chan 2007). 
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NPC has emerged as a critical health problem in southern parts of China, 
including Hong Kong, and southeast of Asia. In 2003, NPC was the fifth commonest 
cancer in men and tenth in women (Hong Kong cancer registry, 2003). It ranked 
sixth among the top ten cancer killers in 2004 (Hospital Authority report 2004). Such 
a high mortality rate is probably due to poor diagnosis and lack of therapeutic targets. 
In addition, the molecular pathogenesis of NPC remains poorly unknown. Previous 
studies have demonstrated that the complex etiology of NPC is related to the 
interplay of genetic factors, environmental factors and Esptein-Barr virus (EBV) 
infection (Tao and Chan 2007; Wei and Sham 2005). Although certain genetic 
aberrations are reported in NPC (Tao and Chan 2007; Lo and Huang 2002), the 
genetic basis is still far beyond from being fully understood. 
1.5 Genetic and epigenetic changes in NPC 
The development of NPC involves accumulation of multiple genetic and 
epigenetic aberrations, which provide growth advantages for tumor development. 
These genetic aberrations involve both TSGs and oncogenes on multiple cellular 
pathways. From the comprehensive genome-wide studies, multiple genetic defects 
have been reported. High frequencies of genetic losses are consistently observed on 
chromosomes 3p, 9, 11 q, 13q, I4q and 16q, while recurrent chromosomal gains are 
observed on chromosome Iq, 3q, 7p, 8q, 1 Iq and 12 (Lo et al. 2000; Hui et al. 1999). 
Recent comparative genomic hybridization (CGH) studies also delineated several 
critical regions of gains (lq32, 8ql2-23, 1 lq l3 , 12pl2-ql5) and losses (3pl4-24.2, 
9q21-22, 1 lq24-ter, 13q21-22, 14q22-32, 16q22-23) in a more precise manner (Lo et 
al. 2000). The findings of these chromosomal abnormalities provide important clues 
for the search and identification of TSGs and oncogenes that are critical to the NPC 
pathogenesis. For instance, by the use of fluorescence in situ hybridization (FISH), 
two proto-oncogenes, c-myc and Int-2, were found to demonstrate copy number 
gains at 8q and I Iq, respectively (Fan et al. 2000). Even though information of 
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oncogene alterations is still lacking for NPC, a number of candidate genes associated 
with oncogenic activities have been identified, including bcl2, cyclin D1, EGFR, ras, 
c-met, TERC, PIK3CA and p63; these genes are either located in regions showing 
frequent amplification or their activation is due to gain-of-function mutations (Lo et 
al. 2004; Tao and Chan 2007). 
Interestingly, abnormality of several well-studied critical TSGs for other 
types of cancers such as p53 and RB is rarely found in NPC, suggesting that other 
critical TSGs are involved in NPC pathogenesis. In particular, the inactivation of 
TSGs on 3p, 9p and 14q appears to be a critical event, as deletion of these regions 
was detected in almost all micro-dissected NPC samples. Indeed, a number of TSGs 
residing in these regions are frequently inactivated due to promoter methylation or 
deletion, including RASSFIA and BLU at 3p21, and 口16印圓 and pi严 at 9p21 
(Lo et al. 2004). Similar to other types of carcinoma, aberrant epigenetic silencing of 
cancer related genes is also a hallmark feature of NPC. In recent years, several 
important TSGs involved in other carcinomas were also found to be frequently 
silenced by promoter hypermethylation in NPC (Table 1-1), and it is anticipated that 
more epigenetically silenced TSGs for NPC will soon be disclosed. 
It is likely that multiple genetic abnormalities such as inactivation of TSGs 
and over-expression of oncogenes result in the disruption of various cellular 
mechanisms, which in turn drive the NPC progression. It has been suggested that 
alteration of cell cycle regulation by disrupting Rb and p53 pathways appears to be a 
critical event. Inactivation o f p l 6 , a critical cell cycle regulator for G1 checkpoint, is 
frequently found in primary NPC tumors. Loss of functional p i6 may lead to 
constitutional Rb phosphorylation and uncontrolled proliferation of NPC cells. 
Although p53 mutation is rarely found in NPC, functional disruption of p53 pathway 
due to inactivation of pl4 and over-expression of p63 was common in NPC. 
Moreover, /^S-SF//^-associated pathways may also be a critical event, as 
transcriptional silencing of RASSFIA is found in a majority of NPCs but not in other 
20 
head and neck carcinomas. Nonetheless, more studies will be necessary for the better 
understanding of NPC pathogenesis (Lo and Huang 2002; Lo et al. 2004). Also, the 
elucidation of hypermethylated genes does not only provide powerful insights into 
NPC tumorigenesis, it can also help to develop novel screening test for NPC as those 
hypermethylated genes can act as non-invasive tumor biomarkers. 
Table 1-1. Summary of major candidate TSGs inactivated by promoter 
hypermethylation in NPC 
Gene Location Functions Frequency Reference 
BLU 3 p 2 1 . 3 Stress-response, 6 6 % (Qiu ct al. 2004) 
” transcription factor 
CHFR 1 2 q 2 4 . 3 3 checkpoint protein, 6 1 % (Cheung ct al. 2005) 
^ cell cycle regulation 
DAPK 9 q 3 4 . 1 Posit ive mediator of gamma- 750^ (Kwong ct al. 2002) 
1 interferon induced apoptosis 
Cell cytoskeleton organizat ion, 
DLCl 8 p 2 2 . 3 GTPase activator, signal 8 9 % (Seng ct al. 2007) 
t ransduct ion, cell adhesion 
3 P 2 2 . 2 7 1 % (Kwong ct al. 2007) 
Classical cadherin, calcium 
E-cadherin 1 6 q 2 2 . 1 dependent cell-cell adhesion, 5 2 % (Tsao ct al. 2003) 
proliferation, invasion, metastasis 
EDNRB 1 3 q 2 2 G protein-coupled receptor 9 1 % (Lo ct al. 2002) 
D N A repair, sensing and integrating 
• T 10^26 s l ^ ^ r J ^ t h d r p a i ^ S： :二二 e 28% (Won. et a,. .003) 
and genomic stability 
圓 3 P 2 2 . 3 概 （ W � n g e t a l . 2 " ^ 
P!严 9 p 2 1 Stabilizes p53 interacts with M D M 2 5 4 % ( L � 2 0 0 2 ^ " ^ 
�議 9 p 2 1 4 6 % (KwQ„geta 丨 
PCDHIO 4 q 2 8 . 3 Protocadherm cell adhesion and cell- 3 2 % (Ying ct al. 2006) 
cell interaction 
Thyroid-steroid hormone receptor, 
RARB2 3 p 2 4 transcriptional regulator, 8 0 % (Kwong ct al. 2002) 
retinoic acid signalling 
RAS effector protein, Ras-signall ing, 
讀刚 3 p 2 1 . 3 cell ^ ^ a j ^ ^ i ^ c ^ ^ i ^ A 6 7 % (Lo et a. 2001) 
D1 accumulation 
TSLCl l l q 2 3 . 2 C a - / M g - - m d e p e n d e n t cell-cell ~ (Hui ct al. 2003) 
^ adhesion, apoptosis — 
Wnt-signall ing pathway, binds and 
WIFl 1 2 q l 4 . 3 inhibits W N T proteins, protein- 8 5 % (Chan ct al. 2007) 
tyrosine kinase activity 
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1.6 Involvement of 5 q l l - q l 2 and 14q32 in carcinogenesis 
From our previous array-CGH data, chromosome 5ql l - q l2 and 14q32 were 
found to demonstrate frequent loss in NPC (unpublished data). They are selected as 
the target regions for the identification of novel candidate TSGs in the current study, 
the implications of these two regions in various types of cancers is briefly reviewed 
as below. 
1.6.1 Chromosome 5 q l l - q l 2 and carcinogenesis 
In accordance with our findings, genetic abnormality at 5ql l -q l2 has also 
been frequently reported in a number of malignancies including NPC, lung, breast, 
esophageal and colorectal carcinoma, and melanoma. 
LOH on chromosome 5 has been frequently reported in non-small cell lung 
carcinoma (NSCLC), and it appears that LOH on 5ql l -q l2 is a critical event in this 
cancer. For instance, a previous study concerning the involvement of DNA mismatch 
repair genes in NSCLC revealed that 5ql l -q l3 were found to be hemizygously 
deleted in 42% of the NSCLC patients, and the deletion was found to be occurred at 
hMSH3, a mismatch repair gene mapping to 5ql l -q l2 , in 65% of the patients 
(Benachenhou et al. 1998). Another study also reported similar results that LOH on 
5ql 1.2-ql2.2, which encompasses hMSH3, was detected in about 50% of NSCLC 
cases (Mendes-da-Silva et al. 2000). 
The potential of 5ql l -q l2 as a tumor suppressor locus has also been 
suggested in breast cancers. In a previous study examined for the involvement of 
mismatch-repair genes in sporadic breast cancer by microsatellite instability and 
LOH analyses, LOH on 5ql l -ql3, where the mismatch repair gene hMSH3 resides, 
was detected in 23% of patients (Benachenhou et al. 1999). Interestingly, a recent 
study demonstrated that LOH on 5ql2-ql3.1 was detected in more than 75% of 
hereditary breast cancer patient with BRCAl mutation, and a putative homozygous 
deletion on 5ql2.1 was also detected in both the primary tumor and its local 
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recurrence from a BRCAl mutation carrier (Jonsson et al. 2005), suggesting that this 
region harbours genes of importance for BRCAl tumor development. 
The importance of 5ql l -q l2 in colorectal carcinomas is also supported by 
recent studies. It has been demonstrated that allelic loss at the GRL gene locus, 
mapping to 5ql l -q l3 , was found in 27% sporadic colorectal carcinoma patients 
(Wildrick and Boman 1988). Aside from frequent LOH in colorectal carcinomas, 
chromosomal rearrangement at 5ql 1 was also reported in this cancer, indicating that 
this region may confer functional significance to the pathogenesis of colorectal 
carcinoma (Parada et al. 1999). 
Similar to our findings, LOH on 5ql l -q l4 was also reported in a recent study 
on allelotype analysis in NPC, in which potential association between LOH, 
clinicopathological parameters and EBV infection was investigated. From the study, 
5ql l -q l4 presented LOH frequency of more than 30% (Shao et al. 2001). 
Nevertheless, frequent loss of 5ql l -q l2 has been suggested in other carcinomas, 
such as esophageal and male germ cell tumors, and melanoma (Dolan et al. 1998; 
Talwalkar et al. 1998; Murty et al. 1996). 
Information concerning the implication of 5ql l -q l2 in carcinogenesis is now 
emerging, which in turn can facilitate the search for critical cancer-related genes 
within this putative tumor suppressor locus. It has been suggested that loss of this 
region is related to microsatellite instability (MSI) in carcinogenesis, due to the fact 
that this region harbours the mismatch repair gene hMSH3. Even though frequent 
LOH at hMSH3 has been observed in a wide range of malignancies, the implication 
of this region in MSI necessitates further investigations. Nonetheless, this putative 
tumor suppressor locus is currently devoid of report for the presence of cancer-
related genes and/or TSG, but it is likely that a novel TSG(s) within this region will 
soon be disclosed. 
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1.6.2 Chromosome 14q32 and carcinogenesis 
In addition to 5ql l -q l2 , 14q32 was also identified as the major deleted 
region in NPC from our array-CGH (unpublished data). The 14q32 region has been 
recently emerged as a focus of study in cancer research, because abnormalities at 
14q32 such as LOH and translocation have been frequently reported in multiple 
cancers, including NPC, colorectal, esophageal and renal cell carcinoma, and 
neuroblastoma. 
The significance of 14q32 in NPC pathogenesis is now emerging. In addition 
to high frequency LOH on chromosome 3p, 9p and l l q in NPC (Mutirangura et al. 
1998), recent studies have also revealed that LOH on chromosomes 14q is also 
implicated in NPC. Several TS loci on chromosome 14q have been proposed in NPC. 
Previous studies on 14q LOH using 19 polymorphic microsatellite markers spanning 
the entire 14q demonstrated 74.4% LOH (24 of 39) for at least one marker. Three 
minimal regions of loss were identified at 14ql 1.2, 14ql2-ql3 and 14q32-qter 
(Mutirangura et al. 1997). A recent LOH analysis also demonstrated LOH frequency 
of more than 30% at 14q32 in NPC, and a close relationship between LOH on 
chromosome 14q and poor differentiation of NPC tumor cells was also proposed 
(Shao et al. 2002). A more recent study using monochromosome transfer technique 
of chromosome 14 provided functional evidence for the importance of two discrete 
regions of chromosome 14 in NPC (Cheng et al. 2003). With the use of microsatellite 
typing and fluorescence in situ hybridization (FISH), two commonly lost regions 
were identified at 14ql 1.2-ql3.1 and 14q32.1 in the microcell hybrid cells to which 
chromosome 14 was transferred. These results provide evidence that LOH on 
chromosome 14q32 is a common genetic aberration in NPC, and 14q32 may harbour 
critical TSGs that are involved in the NPC oncogenesis. 
It has been suggested that LOH on 14q32 is a common genetic aberration 
event in colorectal carcinoma. A precise allelotyping analysis was performed on 
primary colorectal carcinomas using 6 polymorphic microsatellite markers to 
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determine the precise frequency of LOH at 14q32. It was observed that 50% of the 
tumors showed LOH at one or more 14q32 markers (Bando et al. 1999). Another 
LOH study also showed similar results from which the LOH frequency on 14q32 was 
about 25%, and they also found that there was no significant correlation between the 
extent of LOH and the lymph node metastasis (Ami et al. 1998). 
The importance of LOH on 14q32 is also suggested in esophageal carcinoma. 
Previous allelotype analysis identified 37% of the tumors (12 of 37) showed LOH on 
14q32 at least one locus (lhara et al. 2002). The common region of deletion was 
delineated between loci D14S65 and D14S250, an estimated 8cM spanning 14q32. 
This commonly deleted region well correlates with the one identified in colorectal 
carcinoma (Bando et al. 1999). Most importantly, a recent study using 
monochromosome transfer technique of chromosome 14 into esophageal carcinoma 
cell line provided functional evidence that tumor-suppressive regions of chromosome 
14 are essential for esophageal carcinoma (Ko et al. 2005). They also mapped two 
critical non-randomly eliminated regions of 680-kb and � 2 . 2 - M b to 14q32.13 and 
14q32.33 respectively. These results suggest the functional significance of 14q32 in 
the carcinogenesis of esophageal cancer. 
Besides, extensive studies have demonstrated that 14q32 is frequently 
affected in neuroblastoma (NB), and several tumor suppressor gene loci on 
chromosome 14 for NB have been proposed. Theobald and co-workers suggested the 
presence of at least two putative TS loci on chromosome 14 by using RFLP and 
microsatellite analysis with 13 polymorphic markers spanning the entire 14q 
(Theobald et al. 1999). They showed LOH on 14q32 in 18% of the tumors (19 of 
107). Similar LOH frequency on 14q32 (18%, 83 of 372) was also observed in 
another study using a panel of highly polymorphic microsatellite markers spanning 
the chromosome 14q. A single consensus region of deletion within 14q23-q32 was 
also reported in that study (Thompson et al. 2001), suggesting that one or more TS 
loci may be located in the distal chromosome 14q. A more recent detailed LOH study 
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in 54 primary NB samples using 12 microsatellite markers on 14q32 revealed 31% 
LOH (17 of 54) at one or more markers, and a 1.1 Mb minimal region of loss was 
identified between D14S62 and D14S987 at 14q32 (Hoshi et al. 2000). This result 
provides a more precise and fine deletion mapping of 14q32 in NB. 
Not only 14q32 deletion plays a role in the initiation and/or progression of 
various kinds of tumor, chromosome translocation at 14q32 also has contribution. 
Previous cytogenetic studies have shown that 14q32 translocation is a nonrandom 
structural abnormality in multiple myeloma (MM). For instance, Avet-Loiseau and 
co-workers demonstrated a high frequency (75%, 447 of 653) of 14q32 translocation 
in MM, by performing FISH on a larger group of MM patients. There were two 
frequent 14q32-specific translocations identified, which include t(l 1;14) (ql3;q32) 
and t(4;14) (pl6;q32) observed in 16% (105 of 669) and 10% (68 of 669) MM 
patients (Avet-Loiseau et al. 2003). Nevertheless, amplification of chromosome band 
at 14q32 was also demonstrated in certain types of cancer. Chromosomal gain at 
14q32 was observed in a previous cytogenetic study on oral squamous cell 
carcinoma and thyroid cancer using CGH. Increase of copy number in 14q32 was 
detected in 14 of 24 oral squamous cell carcinomas (Gebhart et al. 1998). It has also 
been reported that amplification on 14q32 was one of the chromosome aberrations in 
thyroid cancer (Chen et al. 1998). Collectively, these results demonstrate 
chromosomal gain at 14q32 may also be a chromosomal abnormality involved in 
cancer formation in addition to translocation. 
As the body of literature concerning genetic aberrations at 14q32 such as 
LOH and translocation is growing, the significance of 14q32 in tumorigenesis is of 
no doubt. Since LOH on 14q32 is identified in various kinds of cancers, this event is 
likely to be a non-random and critical genetic aberration in tumor formation. Even 
though minimal region of deletion on 14q32 is detected in many kinds of cancers, but 
the molecular significance of how LOH on 14q32 acts in tumorigenesis is still 
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obscure. Hence, the next step is to perform detail mapping of TSGs on 14q32 in 
various kinds of cancer and to perform functional studies on the putative TSGs. 
Recently, a gene mapping to 14q32.2, termed MEGS, is suggested to act as 
growth suppressor in human pituitary adenomas (Zhang et al. 2003). MEGS was 
highly expressed in the normal pituitary and cerebellum but was under-expressed in 
GH-secreting tumors and clinically non-functioning pituitary tumors. Colony 
formation assay revealed that exogenous expression of MEG3a could inhibit growth 
and proliferation of several carcinoma cells, suggesting its ability in suppressing 
tumor growth. Also, it has been reported that hypermethylation of the promoter 
region of MEGS is associated with the loss of expression in pituitary tumors (Zhao et 
al. 2005). These data suggest that MEGS is a candidate TSG at 14q32, whose 
silencing is mainly attributed to aberrant DNA methylation. Frankly, the involvement 
of the critical genes residing in 14q32 in tumorigenesis of various kinds of cancers 
still remains largely unknown, and whether a single gene or several genes in 14q32 is 
implicated in the tumorigenesis is yet to be resolved. 
1.7 Clinical implications of epigenetics in cancers 
Although it remains ambiguous of how DNA methylation participates in gene 
silencing and how aberrant methylation alters chromatin structure, the recent findings 
for DNA methylation abnormalities in different types of cancer have already 
provided us insight into the potential clinical applications. With the use of recently 
derived PCR-based techniques such as methylation-specific PCR (MSP; Herman et 
al. 1996), hypermethylated alleles can be detected with a high degree of sensitivity, 
making the use of aberrant methylation events as tumor biomarkers feasible. It is 
possible that we can detect for hypermethylated alleles in cancer patients, in DNA 
derived from biopsy, and body fluids like serum, sputum and urine samples (Dulaimi 
et al. 2004; Belinsky 2004; Esteller et al. 1999c). Several recent studies have 
suggested that this approach might offer some promise for early diagnosis and risk 
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assessment. For instance, cancer-specific methylation can be detected in sputum to 
detect for lung cancer, in pancreatic juice to detect pancreatic cancer, in urine to 
detect bladder cancer, and in free DNA from plasma to detect various cancers. 
Notably, methylation of specific genes can also be linked with prognosis and 
response to chemotherapeutics. For examples, methylation of MGMT was found to 
confer sensitivity to the effects of alkylating drugs used in chemotherapy, and DAPK 
methylation is associated with early recurrence of bladder cancer (Ushijima 2005). 
Epigenetic alterations are now recognised as one of the early events in 
tumorigenesis, indicating that methylation alterations detected in non-cancer cells 
can be applied in cancer risk assessment. If methylation of non-core regions leads to 
methylation of core region of a TSG, it could be used as a risk marker. Furthermore, 
as almost every tumor type appears to harbour multiple independent promoter 
hypermethylation events, a reasonably sized panel of biomarkers (methylated genes) 
can therefore be designed for monitoring cancer risk assessment. Studies are now 
emerging to provide evidence for the use of methylation in risk assessment. It has 
been demonstrated that CpG island methylation of and pi4經an early 
event in oncogenesis of various cancers (Nuovo et al. 1999; Shen et al. 2003). 
Nonetheless, much work remain to validate these approaches, but the use of 
hypermethylation markers now appears as promising approach to define cancer risk 
and early cancer detection (Ushijima 2005). 
Another clinical implication of epigenetic changes concerns the possibility of 
reactivating epigenetically silenced cancer genes in aim of inhibiting cancer growth. 
The utilization of epigenetically silenced genes as therapeutic targets is emerging as 
an effective novel approach in chemotherapy and chemoprevention. Many 
therapeutic agents have been discovered to alter methylation patterns on DNA or the 
histone modifications, and some of these agents are currently being tested in clinical 
trials. The most widely used DNA methylation inhibitors are the nucleoside 
analogues, such as the prototype inhibitors, 5-azacytidine (5-Aza-CR) and 5-aza-
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2'deoxyctidine (5-Aza-CdR). They are found to be powerful inhibitors of DNA 
methylation and able to induce expression of epigenetically silenced genes and cell 
differentiation (Egger et al. 2004). Both nucleoside analogues are converted to the 
deoxynucleotide phosphates and are then incorporated in place of cytosine into 
replicating DNA, which in turn inhibits DNA methylation by DNMTs. Subsequently, 
reactivation of genes including apoptotic genes and cell-cycle regulators (such as pl6) 
takes place, leading to cell death and cell-cycle arrest (Bender et al. 1998). 5-Aza-CR 
and its derivatives have been used with some therapeutic results, especially in 
treating hematopoietic malignancies, and recent clinical trials have demonstrated that 
low-dose exposures lead to greater response and are associated with lower toxicity 
(Egger et al. 2004). 
Epigenetic silencing is almost universally linked with histone deacetylation, 
which is catalyzed by HDACs. A number of therapeutic drugs have been designed to 
inhibit HDAC activity either globally or specifically, such as Trichostatin A (TSA), 
phenylbutyrate and SAHA (Egger et al. 2004). However, the exact mechanism by 
which these inhibitors mediate anti-tumor activity remains largely unknown. The 
underlying hypothesis is that accumulation of acetylated histories results in 
reactivation of epigenetically silenced genes, TSGs in particular, and/or suppression 
of oncogenes, eventually to bring about anti-tumor activity. For instance, p21, a cell-
cycle kinase inhibitor responsible for cell-cycle arrest in G1 and G2 phases, has 
shown to be up-regulated in tumor cells upon the treatment of HDAC inhibitors in 
the absence of p53 (Xiao et al. 1999). Besides, it is suggested that hyperacetylation 
of histories would result in genomic instability, which in turn triggers cell-cycle 
checkpoints. Even though some of the HDAC inhibitors are being used in clinical 
trials, it is crucial to elucidate the mechanism of how these agents work so as to 
increase the precision of this approach (Egger et al. 2004). 
The interplay between DNA methylation and histone modifications in cancer 
development has also fueled the idea of combining the use of DNA methylation 
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inhibitors and HDAC inhibitors. A number of studies have demonstrated that the two 
agents can act synergistically in reactivating gene expression. Moreover, a recent 
study has shown a strong synergy between 5-aza-CdR and phenylbutyrate in 
prevention of murine lung cancer. Also, it might be advantageous to sensitize cells 
by epigenetic therapy followed by treatment with chemotherapy (Egger et al. 2004). 
Nonetheless, these epigenetic drugs now represent a promising avenue for better 
development of cancer therapeutics, but more studies are essential to prove the 
validity of such approaches in cancer therapy. 
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Chapter 2 Aims of study and Research plan 
The pathogenesis of human cancers is a multi-factorial and complex process, 
which involves accumulation of multiple genetic and epigenetic changes. These 
changes will in turn lead to aberrant gain-of-function or activation of oncogenes and 
loss-of-function or inactivation of tumour suppressor genes (TSGs). The 
identification of cancer-related genes such as TSGs will provide better understanding 
of the molecular basis of cancer pathogenesis, but the current list of well-identified 
TSG is limited. This prompted us to identify novel TSG to understand the molecular 
pathogenesis of cancer. 
Chromosome loci demonstrating frequent losses can flag regions likely to 
harbor TSGs. NPC, a prevalent malignancy in Southern China including Hong Kong, 
was used as a cancer model for the identification of critical putative TSG loci. An 1-
Mb whole-genome wide array-CGH was carried out previously in our laboratory to 
detect frequent imbalanced chromosome regions in a panel of NPC cell lines, and 
from which several frequently deleted chromosome regions were identified. In the 
current project, I focused on two putative loci mapping to 5ql l -q l2 and 14q32.2-
q32.31, respectively. So far, there are limited TSGs characterized at these regions, it 
is speculated that there are more TSGs remain to be elucidated. 
Indeed, inactivation of TSGs can be mediated through a combination of 
genetic (mutation of one allele or LOH) and epigenetic (methylation of another allele) 
inactivation, epigenetic inactivation of both alleles, or biallelic genetic inactivation. 
As reviewed in Chapter 1, apart from genetic abnormalities, epigenetic aberrations 
such as DNA methylation have been recognized as a common mechanism for the 
inactivation of TSGs in cancers. Based on the rationale that the critical TSGs are 
frequently inactivated by epigenetic mechanisms instead of genetic alterations, the 
objective of the current project was to identify novel epigenetically silenced 
candidate TSGs residing on 5ql l -q l2 and 14q32.2-q32.31 by using an integrative 
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genomic and epigenetic approach. Not only can the findings of this project lead to 
better understanding of the molecular basis of carcinogenesis, the identified silenced 
genes can also act as potential targets for the development of non-invasive tumour 
markers for cancer diagnosis and the new cancer therapeutic strategies. The research 
plan is given as below. 
1) To screen for candidate TSGs at 5 q l l - q l 2 and 14q32.2-q32.31 
A preliminary screening was first performed to screen for candidate TSGs for 
further analyses. The hallmark feature of TSGs is that their function is lost in tumour 
cells, which can be restored by reintroduction of a normally functioning protein with 
concomitant reversion of tumorigenicity. Loss-of-function of TSGs can be 
accompanied by transcriptional silencing or down-regulation, which specifically 
occurs in the tumor cells. Based on this feature, we sought to identify the down-
regulated genes in a panel of carcinoma cells using NPC as the cancer model. 
Differential expression profiling of all the candidate genes residing in these two 
putative TS loci was examined in a panel of NPC cell lines and normal upper 
respiratory tract tissues by semi-quantitative RT-PCR. By comparing the expression 
level in normal tissues, the genes that showed significant down-regulation in a 
majority of NPC cell lines were selected as candidate genes for further analyses. 
2) To examine the expression profile of candidate genes in multiple 
carcinomas 
It is noteworthy that frequent silencing of a TSG may not be restricted to one 
specific cancer type but, instead, may also occur in multiple carcinomas (Ying et al. 
2006). In addition to expression analysis in NPC, the expression level of the 
candidate genes was also assessed in a large collection of cell lines of multiple 
carcinomas, including ESCC, HCC, RCC, lung, breast, gastric and colorectal 
carcinomas. 
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3) To elucidate the role of DNA methylation in the silencing of the 
candidate genes 
As reviewed in Chapter 1, DNA methylation can act as a sole mechanism for 
the inactivation of the cancer-related genes. In fact, there is compelling evidence that 
a TSG candidate(s) within a region of interest need not be mutated or homozygously 
deleted but is often silenced by promoter methylation (Balmain 2002; Dammann et al. 
2001; Hui et al. 1999). Based on this, I sought to examine the methylation status of 
the candidate genes in different types of carcinoma cell lines. In this regard, 
methylation-specific PCR (MSP; Herman et al. 1996) and bisulfite genomic 
sequencing (BGS; Frommer et al. 1992) were adopted for the analysis of the 
methylation status of the regulatory region of the candidate genes. Correlation was 
then made between the methylation status and mRNA expression level of the 
candidate genes. 
To demonstrate that DNA methylation plays a direct role in the silencing or 
down-regulation of the candidate genes, expression of the candidate genes was 
assessed in cell lines that were treated with 5-Aza-CdR (demethylating drug) or in 
combination with TSA (HDAC inhibitor). Restoration of gene expression after 
pharmacologic demethylation would indicate the direct participation of DNA 
methylation in gene silencing. 
4) To examine the tumor suppressor role of the candidate genes 
A crucial step in identifying a TSG is the functional characterization of the 
candidate gene. Our interest thus lies on whether the candidate genes possess tumour 
suppressor function; that is, whether the down-regulation or silencing of the gene is 
advantageous to tumour growth. To address this, in vitro functional study using 
monolayer colony formation assay and soft-agar assay was performed to examine the 
tumour cell growth inhibiting ability of the candidate genes in multiple tumor cells. 
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Chapter 3 Materials and Methods 
3.1 Cell lines and normal tissues 
A series of 67 multiple tumor cell lines were included in the current study. 
These included five NPC (C666-1, CNEl , HKl , HNEl and HONEl), 17 ESCC 
(ECl, EC18, EC 109, HKESCl, HKESC2, HKESC3, KYSE30, KYSE70, KYSE140, 
KYSE150, KYSE180, KYSE270, KYSE410, KYSE450, KYSE510, KYSE520 and 
SLMTl), 13 HCC (Hep3B, HepG2, Huhl , Huh4, Huh6, Huh7, Mahlava, SNU387, 
SNU398, SNU423, SNU449, SNU475 and SLMT-1), three colorectal carcinoma 
(HT-29, LoVo and HCT116), five lung carcinoma (A549, H-1299, H2126, HI395 
and H292), ten breast carcinoma (BT549, MB231, MB468, MCF-7, T47D, ZR-75-1, 
SK-BR-3, YCC-Bl, YCC-B2 and YCC-B3), ten gastric carcinoma (KatoIII, YCCl, 
YCC2, YCC3, YCC6, YCCl, YCC9, YCCIO, Y C C l l and YCCl6) and four RCC 
(A498, Caki, HH050 and HH244) cell lines. 
Several immortalized epithelial cell lines, which demonstrate many features of 
normal epithelial cells, was included in this study. This included an immortalized 
nasopharyngeal epithelial cell line NP69 (Tsao et al. 2002), three immortalized 
esophageal epithelial cell lines NEl , NE2 and Het-IA (Stoner et al. 1991), one 
human embryonic kidney epithelial cell line 293HEK and two human mammary 
epithelial cell lines HMEC (Lonza Bioscience, Switzerland) and HMEpC (Applied 
Biosystems, Foster City, CA). HCTl 16 with double genetic knockout of DNMTl and 
DNMT3B (HCT116/DK0, gift of Bert Vogelstein, Johns Hopkins) was included for 
methylation study; the cell line was maintained in complete growth medium 
supplemented with either 0.4 mg/ml genecitin or 0.05 mg/ml hygromycin. 
Normal human adult and fetal tissue RNA samples were purchased 
commercially (Stratagene, La Jolla, CA, USA and Ambion Inc., Austin, TX, USA). 
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3.2 Routine cell line maintenance 
The cell lines were routinely cultured in the required growth medium 
supplemented with 10% FBS and 1% penicillin/streptomycin. The flasks were kept 
in a 37°C incubator, supplied with humidified atmosphere containing 5% C O � . Once 
the cell confluency reached 70-80%, cells were sub-cultured. In brief, cells were first 
detached with 1-2 ml of trypsin for 5 minutes at 37°C. The trypsin was then 
neutralized with an equal volume of complete growth medium, and the cell 
suspension was centrifuged for 5 minutes at 1,000 rpm to pellet down the cells. 
Supernatant was then discarded and the pellet was resuspended in complete growth 
medium. Appropriate amount of cell suspension was then added into new culture 
flask containing fresh complete medium. Cells at 70-80% confluency were harvested 
and then subjected to RNA and/or DNA extraction. 
3.3 Drug treatments 
For demethylation treatment of cell lines with 5-Aza-CdR (Sigma-Aldrich 
Corporation, St. Louis, MO), cells were diluted to 1 x lOVml and allowed to grow 
overnight, 5-Aza-CdR was added to the medium to a final concentration of 10 \xM. 
Cells were allowed to grow for 3 days, with changing of medium containing 5-Aza-
CdR every 24 hours, and then harvested for DNA and RNA. For the treatment 
combining 5-Aza-CdR and Trichostatin A (TSA) (Cayman Chemical Company, Ann 
Arbor, MI), cells were first treated with 5-Aza-CdR for 3 days and subsequently with 
TSA (100 ng/ml in DMSO) for an additional 24 hours. After drug treatment, cells 
were harvested and subjected to DNA and total RNA extraction. 
3.4 Total RJNA extraction 
Total RNA was extracted by TRI® Reagent (Molecular Research Center, 
Cincinnati, OH). Cells at 70-80% confluence were harvested for RNA. Culture 
medium was first discarded and cells were collected by centrifugation. Cells were 
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lysed directly with 1 ml TRI Reagent per 10 cm culture dish area, and the cell 
lysate was passed through a pipette for several times. The lysate was then subjected 
to vortex until homogenous, and the homogenate was kept at room temperature for 5 
minutes. 0.2 ml of chloroform was added for every 1 ml of TRI® Reagent used, and 
the mixture was vortex for 15 seconds and incubated at room temperature for 3 
minutes. After that, the mixture was centrifuged at 12,000 g for 15 minutes at 4°C. 
From this, the mixture was separated into a lower phenol-chloroform phase, 
interphase, and the colorless lower aqueous phase (contains RNA). The upper 
aqueous phase was then transferred into a new microcentrifuge tube, and the RNA 
was precipitated by adding 0.5 ml of isopropanol per 1 ml of TRI® Reagent used for 
the initial homogenization. The sample was stored at room temperature for 10 
minutes and the RNA pellet was subsequently obtained by centrifugation at 12,000 g 
for 15 minutes at 4°C. After that, the supernatant was removed and the RNA pellet 
was washed with chilled 1 ml 75% ethanoL The RNA pellet was air-dried following 
centrifugation at 7,500 g for 5 minutes at 4°C. Finally, the RNA pellet was dissolved 
in R N A s e c u r e ™ resupension solution (Ambion Inc., Austin, TX, USA) and 
quantified by spectrophotometry as mentioned below. The RNA was stored at -80°C 
until further uses. 
3.5 Genomic DNA extraction 
The interphase and the lower phenol-chloroform organic phase, which 
contained the genomic DNA, were subjected to genomic DNA extraction. In brief, 
the leftover aqueous phase overlying the interphase was first removed, and then 0.3 
ml of 100% ethanol was added to the remaining interphase and organic phase for 
every 1 ml TRI® Reagent added at the initial step. The samples were incubated at 
room temperature for 3 minutes, and subjected to centrifugation at 2,000 g for 5 
minutes at 4°C. The supernatant was then removed with care. The DNA pellet was 
washed twice with the same amount of 0.1 M sodium citrate-10% ethanol as the 
36 
T R I � reagent used initially. In each wash, the DNA pellets were incubated in 
washing solution for 30 minutes at room temperature, and then subjected to 
centrifugation at 2,000 g for 5 minutes at 4°C. After that, the DNA pellets were re-
suspended in 75% ethanol (1.5-2 volume of TRI® reagent used) and stored at room 
temperature for 20 minutes. The samples were centrifuged at 2,000 g for 5 minutes at 
4°C. The DNA pellets were air-dried at room temperature. Subsequently, 500 jul of 8 
mM sodium hydroxide was added to the DNA pellet for every 50-70 mg of tissues or 
10x10^ cells. The pellets were allowed to dissolve at 4°C overnight. In addition, the 
pH of the samples was corrected to 8.0 with HEPES buffer according to the 
manufacturer's protocol (Gibco BRL). DNA quantity and quality were checked by 
spectrophotometry. The DNA samples were stored at 4°C until further analyses. 
3.6 General techniques 
3.6.1 Gel electrophoresis 
PCR products and DNA plasmids were routinely separated on 1.8 or 2.0% 
(w/v) agarose gels. In brief, the gel was prepared by adding appropriate amount of 
agarose powder (Cambrex Bioscience, USA) to 100 ml IX TAE buffer, and 
followed by heating in microwave oven until the powder was melted thoroughly. The 
agarose solution was then cooled down and added with ethidium bromide (EtBr). 
The mixture was poured into the gel tray with combs inserted, and allowed to cool 
down and harden. Subsequently, the gel was immersed in Ix TAE buffer, and DNA 
samples added with 6x loading dye were loaded into the wells accordingly. The gel 
was generally allowed to run at 120 V for 25 minutes and was photographed under 
UV illumination (Bio-Rad, Hercules, CA). 
3.6.2 DNA and RNA quantification 
The amount of nucleic acids was routinely measured by spectrophotometer 
(Beckman DU650). The nucleic acids were first diluted in appropriate amount of 
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Tris-HCL, and then subjected to OD measurement at wavelength 260 nm. In addition, 
the ratio of OD value 260 nm to 280 nm was calculated to check for the purity of the 
nucleic acids. The amount of the nucleic acids was calculated using the OD value at 
260 nm. 
3.6.3 LB medium and LB plate preparation 
LB medium was prepared by dissolving 10 g tryptone, 5 g yeast extract and 
10 g NaCl in a total volume of 1 L distilled water. pH value of the mixture was 
adjusted to 7.5 with NaOH. Finally, the mixture was sterilized by autoclave. 
Appropriate amount of antibiotics (ampicillin: 100 ^ig/ml; kanamycin: 50 |ig/ml) was 
added to the sterilized LB medium prior to use. 
LB agar medium was prepared by dissolving 15 g agarose, 10 g tryptone, 5 g 
yeast extract and 10 g NaCl in a total volume of 1 L distilled water, and the mixture 
was then subjected to autoclave. The agar medium was cooled down to about 55°C 
and appropriate amount of antibiotics (ampicillin: 100 |ig/ml; kanamycin: 50 |ag/ml) 
was added and followed by stirring. About 25-30 ml of the agar medium was poured 
into a 10 cm petri-dish. The agar plates were allowed to solidify at room temperature. 
The plates were stored at 4°C for subsequent uses. 
3.6.4 Plasmid extraction 
3.6.4a Mini-scale preparation of plasmid DNA 
Bacterial colony picked from agar plates was cultured at 37°C overnight 
(-12-15 hours) in an inoculation tube containing 1.5 ml LB medium and appropriate 
amount of antibiotic with shaking at 250 rpm. About 1.3 ml of culture medium was 
then transferred into an eppendorf tube (1.5 mL) and the bacteria were spun down at 
8,000 rpm for 1 minute. The supernatant was removed by aspiration. The bacterial 
pellet was resuspended in 150 |LI1 Solution I (50 mM glucose, 25 mM Tris-Cl, 10 mM 
EDTA and 0.5 mg/mL RNase A) and incubated at room temperature for 10 minutes 
38 
following vortexing. The bacteria were then lysed with 300 )il Solution II (200 mM 
NaOH and 1% SDS), which was freshly prepared prior to addition. The mixture was 
kept on ice for 3-5 minutes following gentle mixing. The lysate was neutralized with 
255 )il chilled Solution III (60 ml of 5M glacial acetic acid added with 11.5 ml 
glacial acetic acid and 28.5 ml H2O; pH5.2) and incubated at room temperature for 
10 minutes. The mixture was then centrifuged at 14,000 rpm for 15 minutes at room 
temperature. After centrifugation, about 550 |il of supernatant containing the plasmid 
DNA was carefully taken out and transferred into a new tube. The plasmid DNA was 
precipitated with 330 |al isopropanol, and the mixture was incubated for at least 15 
minutes at room temperature. The plasmid DNA was centrifuged at 14,000 rpm for 
10 minutes at room temperature. The supernatant was removed by aspiration, and the 
plasmid pellet was washed with 800 |il of 70% ethanol. The plasmid was centrifuged 
again at 10,000 rpm for 5 minutes. The ethanol was removed by aspiration and the 
plasmid pellet was air-dried for 15 minutes at room temperature. At last, the pellet 
was dissolved in 40 |al autoclaved distilled water and stored at 4°C prior to 
subsequent analysis. 1 |al of total volume was subjected to gel electrophoresis for 
checking the quality of the plasmid. 
3.6,4b Large-scale preparation of endotoxin-free plasmid DNA 
Large-scale preparation of endotoxin-free plasmid DNA, which was used for 
transfection, was performed by using QIAGEN EndoFree® Plasmid Midi Kit 
(QIAGEN, Germany) according to the manufacturer's protocol. 
3.6.5 DNA sequencing 
BigDye^ v3.1 terminator sequencing (Applied Biosystems, Foster City, CA) 
was used for DNA sequence analysis. The sequencing reaction mix was assembled as 
1 |al DNA template, I \x\ BigDye and 0.5 |al of 1.6 jaM sequencing primer in a total 
reaction volume of 5 |al. Samples were cycled as 96°C /15s, 52°C /15s and 60°C 
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/2min for 25-30 cycles in a MJ DNA Engine Dyad® Thermal Cycler (MJ research, 
Waltham, MA). The reaction mixtures were then subjected to purification. Briefly, 
0.5 |al of 3 M sodium acetate and 12.5 |iil of 95% ethanol were added to each sample 
for precipitation, and the mixtures were then incubated for 30 minutes in darkness. 
After that, the mixtures were centrifuged at 14,000 rpm for 15 minutes. The 
supernatant was pipetted out with care, and 100 \i\ of 70% ethanol was added to each 
sample for washing. The samples were subjected to centrifligation again at 14,000 
rpm for 5 minutes. The pellets were air-dried at room temperature in darkness. 
Subsequently, the pellet was dissolved in 12 Hi-Dye for at least 5 minutes in 
darkness. The samples were loaded to an ABI optical 96-well plate for sequencing, 
by the ABI 3100 DNA sequencer (Applied Biosystems, Foster City, CA). 
Sequencing results were analyzed by the ABI Sequencing Analysis software. 
3.7 Reverse transcription-PCR (RT-PCR) 
3.7.1 Reverse transcription (RT) 
Total RNA was extracted from cells using TRI® Reagent as described above. 
The reverse transcription of RNA to complementary DNA (cDNA) was performed 
by using the GeneAmp® RNA PCR kit (Applied Biosystems, Foster City, CA) 
according to the manufacturer's protocol. In brief, 1 |ug of total RNA was used for 
every 20 jul total reaction volume. Appropriate amount of RNA was added in DEPC-
treated water to a final volume of 3.8 |LI1. RNA samples were first denatured at 90°C 
for 5 minutes before RT. The RNA sample was then mixed with other RT reaction 
components including 4 of 25 mM MgCb, 2 of lOx PCR Buffer II, 8 …of 10 
mM dNTP mix, 1 of 50 |LIM random hexamer, 0.2 |LII of RNase inhibitor ( 4 0 U / j L i l , 
Roche Applied Science, Germany) and 1 jul of MuLV reverse transcriptase (50U/|LI1, 
Applied Biosystems, Foster City, CA). The final RT mixtures were kept at room 
temperature for 10 minutes before RT reaction. Subsequently, the mixtures were 
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incubated at 42°C for 1 hour to synthesize the cDNA, followed by incubation at 
99°C for 5 minutes. The cDNA was stored at -80°C until further analyses. 
3.7.2 Semi-quantitative RT-PCR 
A pair of gene specific RT-PCR primers spanning two different exons of each 
candidate gene within the regions of interest was designed. The design of primers 
was based on the mRNA sequence obtained from NCBI Genbank database {Homo 
Sapiens Genome - Build 35.1). RT-PCR was performed using AmpliTaq Gold 
(Applied Biosystem, Foster City, CA), and the components for the PCR mixture was 
shown in the table below. 
Table 3-1. Components of each reaction mixture for RT-PCR 
Components Volume used (^1) Final Concentration 
lOx PCR buffer 1 Ix 
MgCb 0.5 2 mM 
AmpliTaq Gold (5 U/^l) 0.5 1.25 U/50)LI1 
Forward primer (10 |LIM) 0.75 0.6 jiM 
Reverse primer (10 jiiM) 0.75 0.6 |iM 
cDNA template 2.5 about 0.5|ig/50^1 
Autoclave distilled water ^ 
Total volume 12.5 
The PCR was performed in an MJ DNA Engine Dyad® Thermal Cycler (MJ 
research, Waltham, MA) under the following conditions: an initial denaturation at 
95°C for 10 min, 32-37 cycles (94�C for 30 s, 55-60�C for 30 s, and 7 2 � C for 30 s) 
of amplification, and a final extension at 72°C for 10 min. PCR products were 
generally resolved in 1.8% gel and were visualized under UV illumination, and 
documented by the Bio-Rad digital gel documentation system using the Quantity 
One® 1-D analysis software (Bio-Rad, Hercules, CA). Initial study on the 
standardization curves of RT-PCR cycle number versus product yield for cellular 
genes showed that linear amplification occurred between 25 and 40 cycles (data not 
shown). Therefore, 32-37 cycles of PCR were used for our semi-quantitative RT-
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PCR analysis. Glyceraldehyde 3-phosphate dehydrogenase {GAPDH) was used as an 
internal control for RNA integrity, and 25 cycles were used for amplification. 
3.8 Methylation analysis 
3.8.1 Sodium bisulfite modification of DNA 
Bisulfite modification of DNA was carried out by the use of sodium 
metabisulfite (Sigma-Aldrich Corporation, St. Louis, MO). Genomic DNA (1-5 )Lig) 
was first denatured with NaOH at a final concentration of 3 M, and incubated for 15 
minutes at 37°C. Meanwhile, fresh solutions of 10 mM hydroquinone and 2.4 M 
sodium metabisulfite (Sigma-Aldrich Corporation, St. Louis, MO) were prepared. 
The tube containing the mixture was inverted gently to dissolve the sodium 
metabisulfite. pH value (5.0-5.2) was then checked. Once the metabisulfite was 
completely dissolved, 210 jul of 10 mM hydroquinone (final concentration of 0.5 mM) 
was added into the sodium metabisulfite solution. 333 |il of the sodium 
metabisulphite/hydroquinone solution was subsequently added to the denatured DNA. 
The reaction was overlaid with mineral oil (Sigma-Aldrich Corporation, St. Louis, 
MO) and incubated at 55°C in darkness for 4 hours. The reaction mixture was 
carefully transferred from beneath the oil to a new 1.5 ml eppendorf tube and the free 
bisulfite was desalted by QIAEX II DNA Clean-Up System (Qiagen, Germany), 
according to the manufacturer's protocol. The DNA was then dissolved in 50 \i\ of 
TE buffer. 
For post-bisulfite treatment, the DNA was denatured by NaOH at a final 
concentration of 0.3 M. Samples were incubated for 15 minutes at 37 °C and 
followed by neutralization using ammonium acetate (pH 7.0) at a final concentration 
of 3 M. pH value of the samples were then adjusted to below 7.0 with sodium acetate. 
The bisulfited DNA was extracted using QIAEX II (Qiagen, Germany), according to 
the manufacturer's protocol. Lastly, the bisulfited DNA was eluted in TE (20 ul/ug 
DNA) and stored at -20°C until further analyses. 
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3.8.2 CpG island analysis 
CpG island located on the region spanning the core promoter, exon 1 and 
intron 1 of the genes of interest was analyzed by the online CpG island searcher 
(http://www.uscnorris.com/cpgislands/cpg.cgi). The criteria for defining CpG island 
are set as CG content > 55%, ratio of observed CpG to expected CpG > 0.65 and 
minimal length of 500bp. 
3.8.3 Methylation-specific PCR (MSP) 
The methylation status of the promoter region of the target genes was 
assessed by MSP (Herman et al. 1996). The bisulfite modification of DNA converts 
the unmethylated cytosine into uracil, rendering the methyl-cytosine unaffected. 
Subsequent PCR reaction converts the unmethylated cytosine into thymidine. This 
property allows us to distinguish the methylated and unmethylated DNA sequences 
with the use of two sets of MSP primers that specifically anneal to methylated or 
unmethylated sequences after bisulfite treatment of DNA. Therefore, two primer sets 
(M and U) were designed within the CpG island identified in each candidate gene. 
The components of the MSP mixture were shown in Table 3-2, and the 
reaction was performed with AmpliTaq Gold (Applied Biosystem, Foster City, CA). 
The bisulfite-treated DNA was amplified with either the methylation-specific primer 
set or the unmethylation-specific primer set for each gene of interest. Prior to MSP, 
all MSP primers were tested and confirmed for not amplifying any unbisulfited DNA. 
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Table 3-2. Components of each reaction mixture for MSP 
Components Volume used (^1) Final Concentration 
lOx PCR buffer ~5 b^ 
dNTPs (2.5 mM each) 1 0.2 mM 
MgCb (25 mM) 1 2 mM 
Forward M or U primer (10 juM) 0.75 0.6 juM 
Reverse M or U primer (10 |LIM) 0.75 0.6 |LIM 
AmpliTaq Gold (5 U/^il) 0.0625 2.5 U/50^1 
Bisulfite-treated DNA 0.5 0.1 ^g/100^1 
Autoclaved distilled water 7.1875 
Total volume 1 2 . 5 | L I 1 
The MSP conditions started with an initial denaturation step for 10 minutes at 
95°C, followed by 40 cycles of amplification of 30 seconds at 94°C, 30 seconds at 
the annealing temperature of each set of MSP primers and 30 seconds at 72°C, and 
ended with a final extension step of 5 minutes at 72°C. MSP products of 
representative samples were confirmed by direct sequencing using BigDye v3.1 
(Applied Biosystem, Foster City, CA), as described above. 
3.8.4 Bisulfite genomic sequencing (BGS) 
The bisulfite modification of DNA converts the unmethylated cytosine into 
uracil, rendering the methylcytosine unaffected. The position and the relative 
abundance of methylcytosine at each CpG dincucleotide within a region of interest 
can be revealed by bisulfite genomic sequencing (BGS; Frommer et al. 1992). The 
bisulfite-treated DNA was PCR-amplified using a pair of BGS primers targeting the 
region of interest. The PCR reaction for BGS was generally the same as the MSP; the 
only difference lied on the final extension time that one hour was used instead of five 
minutes, so that all PCR products are of full-length and adenylated at 3' ends. . The 
PCR product was resolved by electrophoresis, and the band of correct size was 
excised under UV illumination. The PCR products in the gel slice was purified with 
the use of Costar® Spin-X® Centrifuged Tube Filter (Cole-Parmer, Vernon Hills, IL). 
By TA-cloning, the PCR products were cloned into the pCR® 4-TOPO® vector 
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(Invitrogen, Carlsbad, CA), according to the manufacturer's protocol. E. coli strain 
DH5a was transformed with the vector after ligation. Four to six bacterial colonies 
were randomly chosen, and from which the plasmid DNA extracted were subjected 
to sequencing as described. 
3.9 Construction of expression plasmids 
3.9.1 Construction of the MGC80-expressing vector 
MGC80 at chromosome 5ql2 was selected as the target of functional study. 
The full-length cDNA of MGC80 was cloned into the mammalian expression vector 
pcDNA3.1 (+) (Invitrogen, Carlsbad, CA). A pair of cloning primers flanking the 
full-length coding region of MGC80 was designed according to the nucleotide 
sequence retrieved from NCBI Genbank. First, 1 fig of total RNA from normal adult 
testis was reverse-transcribed into cDNA using oligo-dT-AUAP, according to the RT 
protocol described above. A first-round PCR was performed using the cDNA as the 
template, and MGC80-clonl (forward primer) and the adapter primer AUAP, 
following the recipe below. All cloning-PCRs were performed with the use of 
AccuPrime™ Taq DNA Polymerase High Fidelity (Invitrogen, Carlsbad, CA). 
Table 3-3. Components of the reaction mixture for the cloning PCR of MGC80 
Components Volume used (^1) 
lOx AccuPrimeTM PCR Buffer I ~5 
MGC80-Clonl (Forward, lO^iM) 0.5 
AUAP (Reverse, lOfiM) 0.5 
AccuPrimeTM Taq DNA Polymerase High Fidelity (5U/nl) 0.2 
cDNA template 2 
Autoclaved distilled water 19.3 
Total volume 25|il 
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The PCR was performed under the following conditions: an initial 
denaturation at 9 4 � C for 2 min, 30 cycles ( 9 4 � C for 30 s, 5 5 � C for 30 s, and 6 8 � C for 
1.5 min) of amplification, and a final extension at 72°C for 10 min. 
A semi-nested PCR was then performed as above, using the cloning primers 
MGC80-clonl and MGC80-clon2, and 2 |il of the 10-time diluted first round PCR 
product as the template. The PCR product was resolved by electrophoresis, and the 
band of the correct size was excised under UV illumination. The PCR product in the 
gel slice was purified with the use of Costar® Spin-X® Centrifuged Tube Filter 
(Cole-Parmer, Vernon Hills, IL). Then, the PCR product was cloned into the 
pCR®4.0-TOPO® (Invitrogen, Carlsbad, CA), according to the manufacturer's 
protocol. After sequence verification, the insert containing the MGC80 coding region 
was then sub-cloned into the mammalian expression vector pcDNA3.1 (+) 
(Invitrogen, Carlsbad, CA), which contains a neomycin resistance gene, at restriction 
sites Hindlll and Xholl (New England Biolabs, USA). The ligation was performed 
by T4 DNA ligase (Roche Applied Science, Germany). The insert orientation was 
further confirmed by restriction digestion and sequencing. Endotoxin-free 
pcDNA3.1/MGC80 plasmid was prepared by using QIAGEN EndoFree® Plasmid 
Midi Kits (QIAGEN, Germany), as described in the manufacturer's protocol. The 
pcDNA3.1/MGC80 plasmid was used for subsequent transfection experiments. 
3.9.2 Construction of the TUSC14-expressing vector 
TUSC14 was another target of functional study. The full-length coding region 
of TUSC14 was cloned into the mammalian expression vector pcDNA3.1 (Invitrogen, 
Carlsbad, CA). A pair of cloning primers flanking the full-length coding sequence 
was therefore designed according to NCBI Genbank database. In brief, 1 \ig of total 
RNA from normal adult trachea was reverse-transcribed into cDNA using oligo-dT. 
Then, the coding region was PCR-amplified using the components listed below. 
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Table 3-4. Components of the reaction mixture for the cloning PCR of TUSC14 
Components Volume used 請 
lOx AccuPrimeTM PCR Buffer I ~5 
TUSC14-clonl (Forward, 10 ^iM) 0.5 
TUSC14-clon2 (Reverse, 10 |aM) 0.5 
AccuPrimeTM Taq DNA Polymerase High Fidelity (5U/|il) 0.2 
cDNA template 2 
Autoclaved distilled water 19.3 
Total volume ^ 
The PCR was performed under the following conditions: an initial 
denaturation at 9 4 � C for 2 min, 32 cycles ( 9 4 � C for 30 s, 5 5 � C for 30 s, and 6 8 � C for 
1 min) of amplification, and a final extension at 72°C for 10 min. The PCR product 
was first cloned into the pCR®-Blunt-TOPO® vector using the Zero Blunt® TOPO® 
cloning kit (Invitrogen, Carlsbad, CA). After sequence verification, the insert of 
TUSC 14 coding sequence was sub-cloned into the pcDNA3.1 (+) expression vector 
at the restriction site EcoRI. The ligation was performed by T4 DNA ligase (Roche 
Applied Science, Germany). This non-directional sub-cloning utilizing single 
restriction site may result in vectors containing the insert either in sense or antisense 
direction after ligation. Hence, restriction digestion analysis sequence was used to 
check the insert orientation, and followed by sequence confirmation. Lastly, 
endotoxin-free pcDNA3.1 /TUSC 14 plasmid was prepared as described above. 
3.10 Functional analyses 
3.10.1 Monolayer colony formation assay 
One day before the transfection, appropriate amount of tumour cells was 
seeded onto a 12-well plate (l-2xl0Vwell, depending on the growth rate and cell size) 
with each well containing 1 ml of RPMI-1640 medium (Sigma-Aldrich Corporation, 
St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin. The cells were allowed to grow overnight to achieve 50-80% 
confluence. Once the desired cell confluence was reached, the cells were transfected 
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with the empty-vector or the vector containing the cDNA of the gene of interest (0.5 
|ig each) using the FuGENE 6 (Roche Applied Science, Germany) as described in the 
protocol. At 48-hour post-transfection, cells were collected by trypsinization and 
seeded onto 6-well plates at a density of l-BxlO'^/well, and selected for 1-2 weeks 
with medium containing 0.4 mg/ml G418 (Calbiochem, Germany). Total RNA from 
the transfected cells was extracted as described above and treated with DNase 
(Ambion Inc., Austin, TX, USA). Semi-quantitative RT-PCR was used to confirm 
the ectopic expression of the gene of interest. The G418-containing medium was 
replaced for every 3 days. The surviving colonies (> 50 cells/colony) were stained 
and counted. For colony staining, the medium was discarded and the cells were 
rinsed with Ix PBS. After that, the cells were fixed with methanol for 10 minutes. 
Cells were then stained with Genetian Violet (ICM Pharma, Singapore) for 10 
minutes, and rinsed with distilled water. Colony numbers were scored and 
photographed. The assay was performed in triplicate wells and repeated for three 
times. 
3.10.2 Soft agar assay 
Seeding of cells and transfection were performed as above. At 48-hour post-
transfection, 0.5-1x10^ cells were suspended in an upper layer of RPMI 1640 
containing 0.35% agar, 10% FBS and 0.4mg/ml G418, and layered on top of a 
bottom layer (RPMI 1640 containing 0.5% agar, 10% FBS and 0.4mg/ml G418) in 
each well of a 6 well-plate. Selection was performed for 10-14 days with G418. 
Subsequently, surviving colonies were counted and photographed. The assay was 
performed in triplicate wells and repeated for three times. NPC cell lines CNEl and 
HONEl, and colorectal carcinoma cell line HCTl 16, were selected for soft assay 
assays, because these cells were able to grow efficiently in soft agar culture. 
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3.11 Statistical analysis 
Statistical analysis was carried out with Student's t-test by using the software 
GraphPad Prism 3.02 (Graphpad Software, San Diego, CA) ,p < 0.01 was considered 
as statistically significance. 
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Chapter 4 Results 
4.1 Identification of 5 q l l - q l 2 and 14q32.2-q32.32 as frequently deleted 
regions in NPC by aCGH 
A 3040-BAC clone based CGH-array (Sanger Institute whole-genome array) 
with a resolution of � 1 Mb was performed previously to detect genome-wide DNA 
copy number abnormalities in NPC (unpublished data). Among a series of deletions 
identified, 5ql l - q l 2 and 14q32.2-q32.32 were selected as the target regions for the 
identification of novel candidate TSGs in this study. 
The putative TSG locus at 5ql l - q l 2 was further refined as a critical region of 
about 10 Mb, flanking two BAC clones, which were found to demonstrate significant 
reduced signal in a number of NPC cell lines and were located between 5ql 1.2-ql2.3 
(Fig. 4-1). Archived from NCBI Genbank database {Homo Sapiens Genome - Build 
35.1), there are forty-three known candidate genes residing in this 10-Mb region 
(Table 4-2). 
Similarly, a critical region of about 1 Mb was determined as a putative TSG 
locus at 14q32.2-q32.31 (Fig. 4-18). This critical region flanked three BAC clones, 
bA123M6, bA94D19 and bA168L7, which also demonstrated reduced signal in a 
number of NPC cell lines (Table 4-1). According to the NCBI Genbank database, 
there are nine known candidate genes located in this 1-Mb region (Table 4-5). 
Table 4-1. Information of the BAC clones demonstrating significant signal 
reduction, as determined from the array-CGH 
BA C done ID Chromosome location Length (kb) 
bA123M6 14q32.2-32.31 (100,294,975 - 100,462,023) 167.05 
bA94D19 14q32.2-32.31 (100,294,990-100,462,015) 167.03 
bA168L7 14q32.31 (100,855,509 - 101,046,897) 191.39 
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4.2 Identification of novel candidate TSGs at chromosome 5 q l l - q l 2 through 
integrative genomics and epigenetics 
4.2.1 Expression profiling of the candidate genes at 5 q l l - q l 2 in NPC cell lines 
Based on the hallmark feature of the loss-of-function of TSGs in tumor cells, 
I sought to identify the down-regulated or silenced genes within the 10-Mb critical 
region defined at 5ql l -q l2 , which was estimated from array-CGH (aCGH) using 
NPC as the cancer model. As mentioned above, there are forty-three candidate genes 
located within this putative TSG locus. A pair of gene specific RT-PCR primers for 
each gene was designed. By semi-quantitative RT-PCR, differential expression 
profiling of all the candidate genes was examined in a panel of five NPC cell lines 
and normal upper respiratory tract tissues (larynx and trachea), using GAPDH as the 
internal control. Normal nasopharynx tissue was not used because it is difficult to 
obtain, and the limited amount of tissue may not meet the need for the large amount 
of cDNA required by the expression analysis. In this regard, normal larynx and 
trachea were used instead because they are also squamous cells and located at near 
position as the nasopharynx. 
The expression analysis revealed two novel genes at 5ql2, renamed as 
MGC80 and TUSC14 (tumor suppressor candidate 14), and PARTI at 5ql2.1, that 
were highly expressed in the upper respiratory tissues, but significantly down-
regulated or completely silenced in a majority of NPC cell lines (Table 4-2). Hence, 
it was speculated that the down-regulation of these genes might contribute to NPC 
carcinogenesis. 
From the expression analysis, MGC80 and TUSC14 were completely silenced 
in four and all five NPC cell lines, respectively, but were highly expressed in the 
normal upper respiratory tract tissues. For MGC80, it is a previously unstudied gene 
located at 5ql2, and is predicted to code for a protein containing a RING finger 
domain. Besides, TUSC14, also mapping to 5ql2, was recently identified as a 
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binding protein involved in G protein signalling (Hollinger and Hepler 2002), but its 
role in carcinogenesis has not yet been documented. It was speculated that their 
silencing in carcinoma cells might confer functional significance to NPC 
tumorigenesis; these two genes were therefore selected as TSG candidates at 5ql 1-
q l2 for further analyses. 
Besides, PARTI at 5ql2.1 was significantly silenced in a majority of NPC 
cell lines examined (4/5, Table 4-2). PARTI was hypothesized to be regulated 
indirectly by androgens via the expression of an intermediary factor (Sidiropoulos et 
al. 2001; Lin et al. 2000). However, according to the NCBI Genbank database, the 
mRNA reference sequence for PARTI was reported as a nonsense-mediated mRNA 
decay (NMD) candidate and was permanently suppressed during the course of study. 
Based on this dubious data, PARTI was not selected as a candidate for subsequent 
studies. 
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Figure 4-1. Schematic diagram showing the location of the putative TSG locus 
mapping to 5ql l -q l2 . The putative TSG locus maps to 5ql 1.2-ql2.3. This region 
flanks two BAC clones demonstrating significant signal reduction, as determined 
from the aCGH, and the relative positions of the BAC clones were indicated. TSG, 
tumor suppressor gene. 
Table 4-2. Summary of the expression analysis of candidate genes within the 
TSG locus at 5q l l -q l2 in a panel of NPC cell lines and normal upper 
respiratory tract tissues. The expression level of the candidate genes was compared 
in five NPC cell lines, and the normal upper respiratory tract tissues including larynx 
and trachea, by semi-quantitative RT-PCR. Three down-regulated genes, PARTI, 
TUSC14 and MGC80, were highlighted in the table. MGC80 and TUSC14 were 
selected as targets for further studies. 
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4.2.2 MGC80 as a target of study at 5ql2 
4.2.2a Ubiquitous expression of MGC80 in normal human tissues and frequent 
down-regulation in multiple tumor cell lines 
Nucleotide sequence revealed that the MGC80 cDNA contains a single open 
reading frame predicted to contain a RING finger domain (Fig. 4-2A). It was selected 
as a target candidate for further analysis, as it demonstrated frequent silencing in the 
expression profiling experiment. In fact, TSGs are featured by frequent down-
regulation during carcinogenesis. In this regard, it is of interest and concern to 
investigate whether MGC80 is also under-expressed in other tumors, other than in 
NPC. MGC80 expression was first determined in a panel of normal human tissues 
and a large collection of multiple carcinoma cell lines by semi-quantitative RT-PCR. 
MGC80 was highly expressed in various human adult and fetal tissues, such as 
esophagus, stomach, liver, colon, breast, lung and kidney (Fig. 4-2). 
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Figure 4-2A. Schematic transcript structure of MGC80. The transcription start 
site is indicated by curved arrow, and the location of CpG island is shown on the 
figure. The relative positions of RT-PCR primers are indicated by black arrows. 
Figure 4-2B. Expression of MGC80 in human normal tissues. MGC80 was 
broadly expressed in normal human adult and fetal tissues, as determined by semi-
quantitative RT-PCR, with GAPDH as an internal control. Sk. muscle, skeletal 
muscle. 
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In contrast to its high expression in normal tissues, MGC80 expression was 
significantly reduced or completely silenced in 100% NPC (5/5), 53% ESCC (9/17), 
500/0 breast (5 / I 0), 31 % HCC (4/13), 400/0 lung (2/5), 50% gastric (5/10), 100% 
colorectal (3 /3) and 500/0 renal cell carcinoma (RCC, 2/4) cell lines (Fig. 4-3 and 
Table. 4-3). Notably, MGC80 was highly expres?ed in all immortalized epithelial cell 
lines examined, including the immortalized nasopharyngeal epithelial cell line NP69 
(Tsao et al. 2002), three esophageal epithelial cell lines NE 1, NE3 and Het-l A, two 
human mammary epithelial cell lines HMEC and HMEpC, and the human embryonic 
kidney epithelial cell line HEK293 (Fig. 4-3). Taken together, these results 
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Figure 4-3. Expression of MGC80 in multiple tumor cell lines. MGC80 was found 
to be frequently silenced or down-regulated in various carcinoma cell lines when 
compared with the corresponding normal tissues, as determined by semi-quantitative 
RT-PCR using GAPDH as the internal control. The immortalized cell lines are 
underlined. 
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4.2.2h Methylation analysis of MG~r:;80 
Aberrant methylation of DNA in promoter region harboring a CpG island is 
regarded as a key mechanism whereby cancer-related genes, TSGs in particular, can 
be silenced during carcinogenesis (lones and Baylin 2002; lones and Baylin 2007). It 
was speculated that the silencing of MGC80 m.ight be mediated through epigenetic 
regulations, such as DNA hyperrnethylation. With the use of online CpG island 
searcher (http: //www.uscnorris.com /cpgislands/cpg.cgi). MGC80 was found to 
harbor a typical CpG island of about 700p around the first exon (Fig. 4-4). 
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CpG Is/and ________________ .. ~: 
72Sbp 
Figure 4-4. Schematic structure of the MGC80 CpG island. The CpG island 
covers the 5' upstream region of MG~C80 including the exon 1. MSP primer sites and 
BGS region are indicated. Each short vertical line represents one CpG site. 
To explore the possibility that silencing of MGC80 may be attributed to 
aberrant hypermethylation at this promoter CpG island, the methylation status of this 
CpG island was first assessed in various carcinoma cell lines by MSP, in which two 
sets of primers targeting the methylated or unmethylated alleles were designed within 
the CpG island. MSP results revealled that MGC80 CpG island was methylated in 
various carcinoma cell lines with reduced or no expression (Fig. 4-5). It is also 
noteworthy that no methylation was detected in all seven immortalized but non-
transformed epithelial cell lines (NP69, NE-I , NE-3, Het-l A, HMEC, HMEpC and 
HEK293) in which MGC80 was highly expressed. Briefly, MGC80 methylation was 
detected in all NPC (5/5) and colon carcinoma (3/3) cell lines, as well as in 47% 
esophageal (8/ 17), 600/0 breast (5/10), 400/0 lung (2/5), 40% gastric (4/10) and 50% 
renal cell (2/4) carcinoma cell lines (Table 4-3). As expected, methylation was rarely 
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detected in the HCC cell lines (2/16), of which almost all demonstrated high 
expression of MGC80. In short, the methylation status of MGC80 CpG island was 
found to be inversely well correlated with MGC80 expression in different carcinomas. 
These data suggest that hypermethylation of MGC80 is likely tumor-specific. 
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Figure 4-5. Methylation analysis of MGC80 in various tumor cell lines by MSP. 
The methylation status of the MGC80 CpG island was assessed by MSP. The CpG 
island was found to be hypermethylated in carcinoma cell lines with reduced or no 
expression, but unmethylated in all the immortalized epithelial cell lines (underlined). 
Expression status of MGC80 in the corresponding cell line was shown under each 
panel. +, with expression; 士，with weak expression; no expression; M, methylated; 
U, unmethylated. 
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Table 4-3 Summary of frequency MGC80 down-regulation and methylation in 
various cell lines 
• , Frequency of MGC80 down- Frequency of 
regulation or silencing methylation 
Carcinoma cell lines 
NPC 5/5(100%) 5/5(100%) 
ESCC 9/17(53%) 8/17(47%) 
Breast Ca 5/10(50%) 5/10(50%) 
HCC 4/13 (31%) 2/13 (15%) 
Gastric Ca 5/10(50%) 4/10 (40%) 
Lung Ca 2/5 (40%) 2/5 (40%) 
Colorectal Ca 3/3 3/3 
RCC 2/4 2/4 
Immortalized epithelial cell lines 
NP69, NEl , NE3, Het-IA, HMEC, 
HMEpC and HEK293 
High-resolution BGS was then performed to assess the methylation status of 
forty-four CpG sites within the MGC80 CpG island in detail. As revealed from the 
BGS results, the CpG sites within the region of interest were extensively methylated 
in carcinoma cell lines lacking its expression, such as C666-1, HKl , KYSE150 and 
HCTl 16 (Fig. 4-6). On the contrary, almost all CpG sites were unmethylated in 
MGC50-expressing immortalized epithelial cell lines, such as NP69, NEl and 
HMEC (Fig. 4-6). The BGS results agree well with the MSP analysis, and 
demonstrate that hypermethylation of MGC80 CpG island is not only restricted to a 
few CpG sites within the CpG island as assessed by MSP but indeed, is in a 
widespread manner. Taken the MSP and BGS result together, it is likely that 
hypermethylation at the promoter CpG island is associated with MGC80 silencing 
during carcinogenesis. 
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Figure 4-6. High-resolution methylation analysis of the MGC80 CpG island by 
BGS. The left panel shows the methylation status of forty-four CpG sites within the 
MGC80 CpG island in representative carcinoma cell lines lacking the expression, 
and immortalized epithelial cell lines, as determined by BGS. One row of circles 
represents an individual allele of the MGC80 CpG island analyzed. The right panel 
shows the MGC80 expression status and MSP results in the corresponding cell line. 
The MSP primers are indicated by black arrows. Open circle, unmethylated CpG site; 
filled circle, methylated CpG site; +, with expression; -, without expression; M, 
methylated; U, unmethylated; open circle, unmethylated CpG; filled circle, 
methylated CpG. 
4.2.2c Restoration of MGC80 expression after pharmacologic and genetic 
demethylation 
In order to gain further insight into the participation of DNA methylation of 
the MGC80 CpG island in gene silencing, several carcinoma cell lines lacking its 
expression and with hypermethylated MGC80 were treated with the DNA 
methyltransferase inhibitor 5-aza-2' deoxycytidine (5-Aza-CdR) alone or along with 
histone deacetylase (HDACs) inhibitor Trichostatin A (TSA). After 5-Aza-CdR 
treatment, MGC80 was dramatically re-expressed (Fig.4-7A). Concomitantly, 
increase of unmethylated MGC80 alleles was observed after drug treatment, as 
revealed by MSP and BGS (Fig. 4-1A and Fig. 4-7C). This indicates that there is a 
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direct link between MGC80 silencing and CpG island methylation. Enhancement in 
reactivation of expression was also observed after treatment with 5-Aza-CdR along 
with TSA in HONEl (Fig. 4-7A), implying that DNA methyltransferase may operate 
in concert with HDACs in the transcriptional silencing of MGC80. 
Similarly, MGC80 expression was also dramatically induced in colorectal 
carcinoma cell line HCT116 with genetc double-knockout of two major DNA 
methyltransferase gene DNMTl and DNMT3B (HCTl 16/DKO), when compared to 
wild-type HCTl 16 (Fig. 4-7B). As expected, the reactivation of MGC80 expression 
was in association with an increase in unmethylated alleles of MGC80, as 
demonstrated by MSP and BGS (Fig. 4-7C). This provides further lines of evidence 
that transcriptional silencing of MGC80 is directly mediated through CpG island 
methylation by DNMTl and DNMT3B. 
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Figure 4-7A. Reactivation of MGC80 expression after pharmacological 
demethylation. MGC80 expression before and after drug treatment was determined 
by semi-quantitative RT-PCR (upper panel) and demethylation was confirmed by 
MSP (lower panel). 
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Figure 4-7B. Restoration of MGC80 expression after genetic demethylation. 
Genetic double-knockout of DNMTl and DNMT3B (DKO) in HCTl 16 resulted in 
induction of MGC80 expression (upper panel) and demethylation (lower panel). 
Figure 4-7C. BGS analysis of the MGC80 CpG island after pharmacologic and 
genetic demethylation. High-resolution methylation mapping of CpG sites by BGS 
confirmed the pharmacologic and genetic demethylation of MGC80 CpG island in 
NPC cell lines and HCTl 16/DKO. On the right are the MGC80 expression status and 
the MSP results. Open circle, unmethylated CpG site; filled circle, methylated CpG 
site; +, with expression; without expression; M, methylated; M/U, both methylated 
and unmethylated alleles are detected, U, unmethylated. 
4.2.2d Functional study of MGC80 in multiple carcinomas 
The frequent silencing of MGC80 in multiple carcinomas prompted us to 
have the idea that its inactivation may be advantageous to tumor growth, which in 
turn implies that MGC80 may function as a TSG. To explore the potential tumor 
suppressor role of MGC80 in different carcinomas, I investigated whether restoration 
of MGC80 expression would suppress the growth of carcinoma cells lacking its 
expression. The full-length coding sequence of MGC80 was first cloned into a 
mammalian expression vector, which was subsequently transfected into a number of 
tumor cell lines with silenced expression and complete methylation, including 
HONEl (NPC), KYSE510 (ESCC) and HCTl 16 (colorectal carcinoma). The colony 
numbers were scored after 1-2 weeks of G418 selection. As revealed from colony 
formation assay, ectopic expression of MGC80 dramatically reduced the colony 
formation efficiency of these tumor cells by 50 to 60% in monolayer culture, in 
comparison with the empty-vector transfectants (Fig. 4-8,/?<0.01). 
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Figure 4-8A. Effect of ectopic MGC80 expression on the clonogenicity of tumor 
cells. HONEl, HCT116 and KYSE510 were transfected with pcDNA3.1/MGC80 or 
empty-vector, and selected with G418. Inhibition of colony formation in monolayer 
culture was observed in pcDNA3.l/MGC80-transfected cells, when compared with 
the empty-vector control. 
Figure 4-8B. Post-transfection expression analysis of MGC80. Total RNA was 
extracted from transfected cells and treated with DNase. RT-PCR was then 
performed to assess their expression levels. Expression of MGC80 was only detected 
in pcDNA3. l/MGC80-transfected cells, but not in the empty vector control. 
Figure 4-8C. Quantitative analyses of colony numbers . The numbers of colony 
were counted after selection. The numbers of colony in each empty vector-
transfected cell line were set to 100%. Values are the mean 士 s.e. of at least three 
individual experiments. P values were calculated using student's t-test. The two 
asterisks indicate statistical significant difference (^<0.01). 
Besides, the effect of restoration of MGC80 on anchorage-independent 
growth of tumor cells was further examined by soft-agar assay using HONEl and 
HCT116 cells. From this, both the colony numbers and size of the tumor cells 
transfected with pcDNA3.1/MGC80 were significantly reduced in soft-agar, 
comparable to the empty-vector control (p<0.01, Fig. 4-9). Taken together, these in 
vitro data provide the first functional evidence that MGC80 can suppress both 





T- * > 100-
尝 1 • • 
o • ir°- • • 
： ^ L - i i _ _ Z . ' . g ^ 60- ^ pcDr4A3.1/MGC80 
① • . . ， . 40- ^m 计 千 
H0NE1 HCT116 
Figure 4-9A. Effect of ectopic MGC80 expression on the anchorage-independent 
growth of tumor cells. HONEl and HCTl 16 cells were transfected with 
pcDNA3.1/MGC80 or empty vector, and selected with G418. Significant inhibition 
of anchorage-independent growth was observed in tumor cells transfected with 
pcDNA3.1/MGC80, when compared with the empty-vector control. 
Figure 4-9B. Quantitative analyses of colony numbers in soft agar. The numbers 
of colony formed in soft agar culture were scored after selection. The numbers of 
colony in each empty vector-transfected cell line were set to 100%. Values are the 
mean 士 s.e. of at least three individual experiments. P values were calculated using 
student's t-test. The two asterisks indicate statistical significant difference (p<0.01). 
4.2.2e Discussion 
In this project, an aCGH was adopted previously to screen for genome-wide 
chromosome copy number abnormalities in NPC, which is a prevalent malignancy in 
Southern China including Hong Kong (Tao and Chan 2007). From this, a 10-Mb 
region mapping to 5ql l -q l2 , which demonstrated frequent copy number loss in NPC, 
was determined as a putative TSG locus. But the presence of TSGs at this region has 
not been documented in any type of cancer. This prompted us to disclose novel 
TSG(s) within this region. The expression status of the candidate genes residing in 
this region was first analyzed by semi-quantitative RT-PCR in a panel of NPC cell 
lines. I found that a novel gene MGC80 residing in 5ql2 demonstrated frequent 
silencing in a majority of NPC cell lines but was expressed at high levels in the 
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normal upper respiratory tissues and NP69, giving clues that MGC80 may be a 
critical TSG within the region. It is also noteworthy that frequent silencing of a TSG 
may not be restricted to one specific cancer type but, instead, may occur in multiple 
carcinomas (Ying et al. 2006). As expected, MGC80 was also significantly under-
expressed in various common cancer types in our locality including ESCC, HCC, 
lung, breast, gastric and colorectal carcinomas. It was speculated that MGC80 
silencing may be a critical contributor in NPC pathogenesis as well as in other tumor 
types, and its silencing may confer advantages to tumor progression. 
DNA promoter hypermethylation has been regarded as a common mechanism 
in TSG silencing in virtually all types of human cancers (Jones and Baylin 2007). 
The upstream region of MGC80 harbours a typical CpG island, which was found to 
be hypermethylated in carcinoma cell lines lacking its expression. Hypermethylation 
at CpG island of MGC80 was inversely well correlated with its mRNA expression in 
all carcinoma cell lines being examined. In particular, its expression was restored 
after treatment with 5-Aza-CdR, suggesting that its silencing in multiple carcinomas 
is directly mediated through DNA methylation. More importantly, monolayer colony 
formation and soft agar assays showed that restoration of MGC80 could strongly 
suppress growth of NPC, ESCC and colorectal carcinoma cells, providing lines of 
evidence that MGC80 may be a novel functional TSG in multiple carcinomas. 
MGC80 is predicted to encode for a protein containing a RING finger domain. 
Despite the fact that our current knowledge is completely devoid of reports for the 
functional role of MGC80 and the functional consequence of MGC80 inactivation in 
tumorigenesis, we may get some insights from previous studies concerning the 
participation of other RING finger-containing proteins in cancer progression. It has 
been proposed that the RING domain is an important module in ubiquitin (lib) 
protein ligases (E3s), which is a critical enzyme involved in protein ubiquitination 
(Fang et al. 2003). Indeed, many RING domain-containing proteins play important 
roles in tumorigenesis, and some of them are critical TSGs involved in various types 
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of cancer. For instance, BRCAl (also known as RNF53), one of the best-
characterised tumor suppressors, contains a RING finger domain at its N-terminal. A 
number of functions have been ascribed to BRCAl, including roles in transcriptional 
regulation, DNA repair, checkpoint control of cell cycle, and induction of apoptosis 
(Venkitaraman 2002). It is suggested that tumor-associated mutations in the RING 
finger domain of BRCAl abrogate its intrinsic E3s activity. Also, a truncated form of 
BRCAl lacking functional RING domain in HCC fails to restore the G2/M 
checkpoint or the radiation protection function of BRCAl (Ruffner et al. 2001). 
Further evidence regarding the ubiquitination functions of BRCAl comes from the 
proteins with which BRCAl associates (Baer and Ludwig 2002). The interacting 
partners of BRCAl include BARDl, BRAP2 and BAPl. Interestingly, BARDl alone 
shows no detectable E3 activity, but the BRCAl-BARDl heterodimer is a more 
potent E3 than BRCAl alone (Hashizume et al. 2001). Also, it has been suggested 
that the binding of the BAPl, an Ub carboxy-terminal hydrolase, through the RING 
domain can potentiate the tumor suppressor function of BRCAl in breast cancer 
(Jensen et al. 1998). Nevertheless, it stills remains unclear whether BRCAl exerts its 
tumor suppressor functions through protein ubiquitination. 
Apart from BRCAl, the mitotic checkpoint regulator CHFR (checkpoint with 
FHA and ringer finger; also known as RNF196) is also a RING domain-containing 
protein. CHFR has a role in chromosome condensation delay in response to mitotic 
stress and is suggested as a potential 'gatekeeper' function for entry into mitosis. 
Also, CHFR was found to be frequently inactivated through promoter 
hypermethylation and its tumor suppressor role has been suggested in a wide range 
of tumors including NPC (Toyota et al. 2003; Cheung et al. 2005). It is likely that 
CHFR silencing may lead to disruption of G2/M checkpoint during carcinogenesis. It 
has also been suggested that CHFR also acts as an Ub ligase and has been shown to 
facilitate ubiquitination and degradation of Plk-1 in Xenopus, thus inhibiting entry 
into mitosis (Kang et al. 2004). However, the exact mechanism by which CHFR 
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activity is regulated and the precise mechanism of CHFR acts in carcinogenesis 
remain largely unknown. 
In addition to intense study on the role of RING domain in BRCAl and 
CHFR, recent studies have now begun to reveal the importance of this domain in 
many other RING-containing tumor suppressors. For instance, it is proposed that 
tumor suppressor function of TRC8/RNF139 is RING-dependent in clear cell renal 
carcinoma (Brauweiler et al. 2007). Due to the fact that many tumor suppressors are 
found to be RING domain-containing proteins, it is no surprise that study on this 
domain would become another focal point in cancer research, as incorporation of this 
small compact domain may confer additional regulatory functions on a protein (Fang 
et al. 2003). 
In short, the current study provided the first evidence that the predominant 
mechanism for MGC80 silencing in multiple carcinomas is epigenetic silencing. 
More importantly, the in vitro functional study showed that MGC80 could suppress 
tumor cell growth, which implies that it may act as a critical TSG at 5ql2. However, 
our current knowledge regarding the functional consequence of loss of MGC80 in 
terms of carcinogenesis is still lacking. It is also unclear whether MGC80 exerts it 
tumor suppressor functions through its RING domain or other unknown protein 
domains. Therefore, further functional analysis will be of paramount importance in 
elucidating its critical role in carcinogenesis. 
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4.2.3 TUSC14 as a target of study at 5ql2 
4.2.3 a TV SCI 4 was broadly expressed in normal human tissues and frequently 
down-regulated in multiple tumor cell lines 
TUSC 14 was another candidate within the putative TSG locus at 5ql l -q l2 . In 
addition to MGC80, TUSC 14 also demonstrated frequent silencing in the expression 
profiling experiment by which I screen for down-regulated genes within the putative 
TSG locus. TUSC 14 was silenced in all NPC cell lines examined (Table 4-2), but 
was highly expressed in the normal upper respiratory tract tissues (larynx and 
trachea). It was speculated that its silencing may also be critical to the NPC 
pathogenesis as well as other types of carcinomas. I first assessed its tissue 
distribution by semi-quantitative RT-PCR. TUSC 14 was found to be expressed at 
high levels in almost all adult and fetal tissues examined, such as esophagus, stomach, 
liver, colon, breast and lung. However, it was moderately expressed in adult lymph 
node, bone marrow, skeletal muscle and placenta (Fig. 4-10). 
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Figure 4-10. Expression analysis of TV SCI 4 in normal tissues. TUSC 14 was 
broadly expressed in all fetal normal tissues and in almost all adult tissues, as 
determined by semi-quantitative RT-PCR. GAPDH was used as the internal control. 
The expression profile of TUSC 14 was further examined in multiple 
carcinoma cell lines. As revealed from RT-PCR, TUSC 14 expression was 
significantly reduced or completely silenced in various carcinoma cell lines, 
including all NPC (5/5) and colorectal carcinoma (3/3) cell lines, 78% ESCC (14/17), 
100% HCC (13/13), 40% breast (4/10), 80% lung (4/5), 90% gastric (9/10) and RCC 
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(4/4) cell lines (Fig. 4-11 and Table 4-4). In particular, TUSC14 was highly 
expressed in a number of immortalized cell lines, including NP69, NE-1 and 
HEK293. Interestingly, its expression was not detected in the immortalized 
esophageal epithelial cell line NE-3, and the human mammary epithelial cell lines 
HMEC and HMEpC. Despite the fact that TUSC14 expression was absent in a 
limited number of immortalized cell lines, which retained many features of normal 
cells, the results are still supportive for the idea that TUSC14 down-regulation or 
silencing occurs specifically in tumor cells, as demonstrated by high expression level 
in normal tissues and frequent silencing in multiple carcinoma cell lines. 
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Figure 4-11. Expression analysis of TUSC14 in multiple tumor cell lines. Semi-
quantitative RT-PCR revealed that TUSC14 was frequently silenced or under-
expressed in various tumor cell lines, when compared with the corresponding normal 
tissues. The immortalized but non-transformed cell lines are underlined. GAPDH 
was used as the internal control. 
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4,2,3b Methylation analysis ofTUSCU 
Aberrant methylation occurring at the CpG-rich 5’ upstream regulatory 
regions is strongly associated with the transcriptional silencing of TSGs (Baylin and 
Herman 2000). For many of the TSGs, genetic abnormalities may not be the sole 
mechanism for TSG suppression in tumors, whereas epigenetic aberrations such as 
DNA methylation are frequently detected and mainly responsible for gene silencing 
(Balmain 2002; Dammann et al. 2001). In this regard, it was speculated that DNA 
methylation might play a major role in TUSC14 transcriptional silencing in tumors. 
A region of about l,000bp spanning the first exon of TUSC14 was identified as a 
typical CpG island (Fig. 4-12) by using the online CpG island searcher 
(http://www.uscnorris.com/cpgislands/cpg.cgi). 
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Figure 4-12. Schematic structure of the TUSCU CpG island. TUSC14 harbors a 
typical CpG island of about Ikb at its 5' upstream region including exon 1. MSP 
primer sites and BGS region are indicated. Each short vertical line represents one 
CpG site. 
To determine whether hypermethylation at this CpG island is associated with 
transcriptional silencing of TUSC14, MSP was first adopted to assess the methylation 
status of this CpG island in multiple carcinoma cell lines with or without its 
expression. TUSC14 hypermethylation was detected in carcinoma cell lines with 
reduced or no expression, such as in all NPC cell lines, whereas unmethylated allele 
was detected in almost all TUSCl4-expressing carcinoma cell lines (Fig. 4-13). Also, 
no methylation was detected in the immortalized but non-trans formed cell lines with 
high TUSCl4 expression, including NP69, NEl , Het-IA and HEK293. The 
frequency of TUSCl4 methylation in various carcinoma cell lines was summarized in 
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Table 4-4’ As expected, nearly all carcinoma cell lines with reduced or no expression 
demonstrated different extent of hypermethylation. Surprisingly, methylation was not 
detected in almost all HCC cell lines and a number of cell lines lacking TUSC14 
expression such as in Y C C l l , YCC16 and A427 (Fig. 4-13). It is likely that 
transcriptional silencing of TUSC14 in these cells may be solely governed by other 
mechanisms such as genetic deletion or post-transcriptional silencing, instead of 
DNA methylation. Since the issue of homozygous deletion was not addressed, more 
studies are therefore necessary to provide a more complete picture of TUSC14 
silencing during carcinogenesis. Nevertheless, the MSP data still show that 
transcriptional silencing of TUSC14 in carcinoma cells is mainly associated with 
CpG island methylation, except for HCC. 
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Figure 4-13. Methylation analysis of T US CI 4 in multiple tumor cell lines by 
MSP. The methylation status of the TUSC14 CpG island was assessed by MSP. 
Hypermethylation of the TUSC14 CpG island was frequently detected in carcinoma 
cell lines with reduced or no expression, but unmethylated in all the immortalized but 
non-transformed epithelial cell lines (underlined). The expression status of TUSC14 
in the corresponding cell line was shown under each panel. +, with expression; 士， 
with weak expression; -, no expression; M, methylated; U, unmethylated. 
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Table 4-4 Summary of frequency of TUSC14 down-regulation and methylation 
in various ceil lines 
Frequency of TUSC14 Frequency of 
Samples down-regulation or methylation 
silencing 
Carcinoma cell lines 
NPC 5/5(100%) 5/5 (100%) 
ESCC 14/17(82%) 14/17(82%) 
Breast Ca 7/10(70%) 5/10(50%) 
HCC 13/13 (100%) 2/13 (15%) 
Gastric Ca 9/10(90%) 5/10(50%) 
Lung Ca 4/5 (80%) 2/5 (40%) 
Colorectal Ca 3/3 3/3 
RCC 4/4 2/4 
Immortalized epithelial cell lines 
NP69, NEl , NE3, Het-1 A, HMEC, . 门 
HMEpC and HEK293 
High resolution BGS was then adopted to further assess the methylation 
status of thirty-nine CpG sites within the TUSC14 CpG island in more detail. The 
thirty-nine CpG sites within the region of interest were extensively methylated in 
several representative carcinoma cell lines lacking the TUSC14 expression (HKl, 
HONEl, KYSE150, KYSE510 and YCCIO), whereas almost all CpG sites were 
unmethylated in two representative immortalized cell lines with TUSC14 expression 
(NP69 and NEl , Fig. 4-14). The BGS results confirmed the MSP analysis. Taken 
together, the methylation analysis show that TUSC14 silencing in multiple 
carcinomas is frequently associated with hypermethylation of the CpG island. 
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Figure 4-14. High-resolution methylation analysis of TVS CI 4 CpG island by 
BGS. The left panel shows the methylation status of the thirty-nine CpG sites within 
the TUSC14 CpG island in several representative carcinoma cell lines lacking its 
expression, and immortalized but non-transformed epithelial cell lines, as determined 
by BGS. One row of circles represents an individual allele of the TUSC14 CpG 
island analyzed. The right panel shows the TUSC14 expression status and MSP 
results in the corresponding cell line. The locations of MSP primers are indicated by 
black arrows. Open circle, unmethylated CpG site; filled circle, methylated CpG site; 
+, with expression; without expression; M, methylated; U, unmethylated. 
4.2.3c Pharmacologic and genetic demethylation reactivated TUSC14 expression 
To explore whether DNA methylation directly mediates the TUSC14 
silencing, several tumor cell lines (HONEl, HKl and KYSE510) with silenced 
TUSC14 expression and hypermethylation were treated with the demethylating drug 
5-Aza-CdR. After 5-Aza-CdR treatment, expression of TUSC14 was significantly 
reactivated (Fig. 4-15A). Expectedly, demethylation at the CpG island was 
concomitantly observed, as demonstrated by MSP and BGS (Fig. 4-15A and Fig. 4-
15C). The fact that demethylation by 5-Aza-CdR can restore the expression of 
TUSC14 implies that DNA methylation is directly responsible for silencing of 
TUSC14. Furthermore, treatment of 5-Aza-CdR along with TSA resulted in the 
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enhancement of TUSC14 re-expression (HONEl ; Fig. 4-15A), suggesting that 
histone deacetylation is also involved in transcriptional repression of TUSC14 in 
carcinoma cells. 
I further assessed whether genetic demethylation could also reactivate 
TUSC14 expression, by using the double-knockout colorectal carcinoma cell line, 
HCTl 16/DKO, in which TUSC14 was completely silenced and hypermethylated (Fig. 
4-15B). TUSC14 expression was dramatically reactivated in this DKO cell line, 
concomitant with an increase in unmethylated alleles (Fig. 4-15B and Fig. 4-15C). 
Similar to the results obtained in drug treatment with 5-Aza-CdR, genetic 
demethylation in CpG island also resulted in reactivation of TUSC14 expression. 
These results strongly suggest that DNMTl and DNMTSB may cooperate together in 
maintaining the methylation of TUSC14 CpG island, of which hypermethylation 
results in transcriptional silencing during carcinogenesis. 
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Figure 4-15A. Reactivation of TVS CI 4 expression after pharmacological 
demethylation. TUSC14 expression before and after drug treatment was determined 
by semi-quantitative RT-PCR (upper panel) and demethylation was confirmed by 
MSP (lower panel). 
73 
Figure 4-15B. Restoration of TUSC14 expression after genetic demethylation. 
Genetic double knockout of DNMTl and DNMTSb (DKO) in HCT116 resulted in 
reactivation of TUSC14 expression (upper panel) and demethylation (lower panel), as 
determined by semi-quantitative RT-PCR and MSP. 
Figure 4-15C. High-resolution methylation analysis of the TUSC14 CpG island 
after pharmacologic and genetic demethylation. High-resolution methylation 
mapping of CpG sites by BGS confirmed the pharmacologic and genetic 
demethylation of TUSC14 CpG island in representative carcinoma cell lines and 
HCTl 16/DKO. On the right are the TUSC14 expression status and the MSP results. 
Open circle, unmethylated CpG site; filled circle, methylated CpG site; +, with 
expression; -, without expression; M, methylated; M/U, both methylated and 
unmethylated alleles are detected, U, unmethylated. 
4.2.3d Functional study of TUSC14 in multiple carcinomas 
The frequent epigenetic down-regulation and silencing of TUSC14 in 
multiple carcinomas provide clues that it may function as a tumor suppressor, whose 
inactivation may favour tumor growth. To test this hypothesis, we investigated 
whether restoration of TUSC14 expression would suppress growth of carcinoma cells 
with silenced expression, by using colony formation and soft-agar assays. We first 
cloned the full-length coding sequence of TUSC14 into a mammalian expression 
vector, and transfected it into a NPC cell line HONEl and a colorectal carcinoma cell 
line HCTl 16. After 1-2 weeks of G418 selection, ectopic expression of TUSC14 
significantly reduced the colony numbers of HONEl and HCTl 16 cells by about 
50% in monolayer culture, comparable to the empty-vector control (p<0.01; Fig. 4-
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Figure 4-16A. Effect of ectopic TUSC14 expression on the clonogenicity of 
tumor cells. HONEl and HCTl 16 cells were transfected with pcDNA3.1/TUSC14 
or empty-vector, and selected with G418. Inhibition of colony formation in 
monolayer culture was observed in cells transfected with pcDNA3.1 /TUSC14, when 
compared with the empty-vector control. 
Figure 4-16B. Post-transfection expression analysis of TUSC 14. Total RNA was 
extracted from transfected cells and treated with DNase. RT-PCR was then 
performed to assess their expression levels. Expression of TUSC 14 was only detected 
in cells transfected with pcDNA3.1/TUSC14, but not in the empty vector control. 
Figure 4-16C. Quantitative analyses of colony numbers . The numbers of colony 
were scored after selection. The numbers of colony in each empty vector-transfected 
cell line were set to 100%. Values are the mean 士 s.e. of triplicate experiments, p 
values were calculated using student's t-test. The two asterisks indicate statistical 
significant difference (p<0.01). 
Besides, soft agar assay revealed that restoration of TUSC 14 expression could 
significantly inhibit the number and the size of colony formed by tumor cells in 
anchorage-independent culture (p<0.01, Fig. 4-17A and Fig. 4-17B). Collectively, 
the ability of ectopic expression of TUSC 14 to inhibit the anchorage-dependent and -
independent growth of tumor cells provides support, at least in vitro, for the potential 
tumor suppressor role of TUSC 14. 
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Figure 4-17A. Effect of ectopic TUSCl4 expression on the anchorage-
independent growth of tumor cells. HONEl and HCTl 16 cells were transfected 
with pcDNA3.1/TUSC14 or empty vector, and selected with G418 for about 2 weeks. 
Significant inhibition of anchorage-independent growth was observed in tumor cells 
transfected with pcDNA3.1 /TUSC14, when compared with the empty-vector control. 
Figure 4-17B. Quantitative analyses of colony numbers in soft agar culture. 
Numbers of colony formed in soft agar culture were scored after selection. The 
numbers of colony in each empty vector-transfected cell line were set to 100%. 
Values are the mean 士 s.e. of at least three individual experiments, p values were 
calculated using student's t-test. The two asterisks indicate statistical significant 
difference (p<0.01). 
4.2,3e Discussion 
In the current project, the aim was to identify novel candidate TSGs at the 
putative 10-Mb TSG locus at 5ql l -q l2 . Intriguingly, apart from the frequent 
silencing of the candidate TSG MGC80, another gene residing in this region, termed 
TUSC 14 (tumor suppressor candidate 14), also demonstrated frequent down-
regulation in multiple carcinoma cell lines including NPC, ESCC, HCC, RCC, breast, 
lung, gastric, and colorectal cell carcinomas. TUSC 14 is recently identified as a novel 
protein that potentially involved in the regulator of G-protein signalling (RGS; 
Hollinger and Hepler 2002), but its role in carcinogenesis has never been reported. I 
found that the silencing of TUSC 14 in multiple carcinomas is mainly attributed to 
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aberrant CpG island hypermethylation. On the other hand, the in vitro functional 
study suggest that TUSC 14 may be a functional TSG, as revealed from the fact that 
ectopic expression of TUSC 14 could strongly suppress clonogenicity of tumor cells 
such as NPC in anchorage-dependent and -independent culture. The data presented 
here open a new research area of TUSC 14 in terms of carcinogenesis. 
G proteins signalling pathways mediate a wide range of critical neuronal 
processes as well as other cellular pathways mainly through the G protein-coupled 
receptors (GPCRs). GPCRs exert their effects by regulating ion channels, second 
messenger production, and protein cascades, which in turn control neuronal activity, 
gene expression pattern, differentiation, migration, and cell plasticity (Neves et al. 
2002). Indeed, G protein-directed signalling is tightly regulated in such a way that 
the signal duration is dictated by the life-time of GTP on Ga subunits, which bind and 
hydrolyze GTP to function as molecular switches. The signal duration can be 
regulated by a group of regulatory proteins, termed RGS (regulators of G protein 
signalling) proteins. RGS proteins exert their regulatory effects by acting as GTPase-
activating proteins (GAPs) to greatly accelerate the rate of GTP hydrolysis and limit 
the lifetime of the active Ga-GTP species (Hollinger and Hepler 2002). Although it is 
evident that RGS proteins directly bind to GPCRs and other cell surface receptors, 
the way of how they are targeted to the receptors and the possible roles of RGS 
proteins have on receptor signalling, other than G protein inhibitors, remain largely 
unknown. TUSC 14 may bind to RGS protein complexes and shuttles them between 
plasma membrane and nucleus However, the precise mechanism necessitates further 
verification, but it is likely that more putative RGS binding proteins, like TUSC 14, 
will soon be disclosed. 
Aside from the role of TUSC 14 in subcellular RGS protein trafficking, the 
novel data presented in my study provide lines of evidence to couple TUSC 14 to 
carcinogenesis. I first demonstrated that TUSC 14 was frequently silenced in multiple 
carcinomas such as NPC, as a consequence of aberrant CpG island methylation. Like 
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many Class II TSGs, silencing of TUSC14 is mainly attributed to epigenetic 
aberrations. Subsequently, the functional study using monolay colony formation and 
soft agar assays showed that ectopic expression of TUSC14 could significantly 
inhibit the growth of NPC and colorectal tumor cells in vitro, giving support for the 
candidacy of TUSC14 to act as a tumor suppressor. 
Even though findings of the role of TUSC14 in subcellular RGS proteins 
targeting are emerging, our current knowledge is totally devoid of its role in 
carcinogenesis. However, we may gain some insights from recent studies on the role 
of RGS proteins. Intriguingly, a member of RGS proteins, RGS6, was recently 
identified as a novel interacting partner of DMAPl and Dnmtl (Liu and Fisher 2004). 
It is also noteworthy that RGS6 was able to inhibit the transcriptional repressor 
activity of DMAPl . As reviewed in Chapter one, DNMTl is a crucial maintenance 
DNA methyltransferase, and its essential role in maintaining CpG island methylation 
in human cancer cells has also been reported (Robert et al. 2003). DMAPl is a 
component of the DNMTl complex involved in repression of newly replicated genes, 
but its transcriptional repressor role has not been clearly defined. Nevertheless, these 
data suggest that RGS6 may have a novel role in regulation of gene expression, 
which is independent of G signalling regulation. 
When taken these previous data into account, a link between TUSC14 and 
carcinogenesis can be proposed. It is possible that in the absence of TUSC14, 
abnormal plasma membrane-nuclear shuttling of RGS members may occur, as a 
consequence of epigenetic inactivation of TUSC14 during carcinogenesis. The 
abnormal subcellular trafficking of RGS6 or the inability to localize into the nucleus 
may in turn disrupt the RGS6-mediated gene regulation in which DNMTl and 
DMAPl may also be involved. It is unsure whether such abnormality would lead to 
inactivation of other TSGs and/or activation of onocogenes, which favour abnormal 
cell growth and cancer progression. Unquestionably, the indirect role of TUSC14 in 
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regulating gene expression through binding with regulatory proteins like RGS6 
warrants further investigation. 
Nevertheless, it is obscure that whether loss of TUSC14 would also lead to 
misallocation of the RGS-Gp5 complexes that are implicated in G signalling 
regulation. It has been reported that GPCR system is abnormally activated in prostate 
cancer and may contribute to tumor progression through activation of G protein 
signalling (Daaka 2004; Dorsam and Gutkind 2007). The inability of RGS proteins to 
regulate GPCR-mediated signallings at the plasma membrane, due to the epigenetic 
silencing of TUSC14, may in turn result in aberrant activation of certain signal 
transduction pathways that promote carcinogenesis. At the moment, it is unclear 
whether these proposed scenarios exist during cancer progression; further studies are 
therefore necessary to clarify these ambiguities. 
In summary, my data demonstrated for the first time that TUSC14 is 
frequently under-expressed or silenced in multiple carcinomas, and its inactivation is 
mainly attributed to aberrant methylation at CpG island. In particular, the in vitro 
functional study suggest that TUSC14 may function as a TSG in multiple carcinomas, 
as revealed from the suppression of clonogenicity of tumor cells by restoration of 
TUSC14. Although the role of TUSC14 in subcellular trafficking of RGS family is 
emerging, its implication in cancer progression has not yet been appreciated. The 
novel findings presented here will help to facilitate studies to unveil the bona fide 
tumor suppressor role of TUSC14 in carcinogenesis, and shed light on the role of 
aberrant G protein signallings in cancer progression. 
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4.3 Identification of candidate TSGs at chromosome 14q32 through 
integrative genomics and epigenetics 
4.3.1 Expression profiling of the candidate genes at 14q32 in NPC cell lines 
Expression profiling of the nine candidate genes within the 1-Mb putative 
TSG locus mapping at 14q32.2-q32.31 (Fig. 4-18) was first performed in a panel of 
NPC cell lines and normal upper respiratory tract tissues (larynx and trachea). From 
this, DLKl and MEGS, both mapping to 14q32.2, were found to be frequently down-
regulated in a majority of NPC cell lines, but expressed at high levels in normal 
upper respiratory tract tissues (Table 4-5). MEGS (maternal imprinted gene 3) is 
potentially non-coding. A pituitary derived MEG3 isoform, termed MEG3a, was 
suggested as a growth suppressor in several tumor cells. Also, it has been recently 
reported that silencing of MEG3 in pituitary tumor was mediated by promoter 
hypermethylation. 
In this study, DLKl [delta-like 1 homolog (Drosophila)] was selected as the 
I4q32 target gene for further analyses. From the expression profiling results, it was 
found to be down-regulated or silenced in four out of five NPC cell lines (Table 4-5). 
DLKl is a paternal imprinted gene that encodes for a transmembrane protein 
containing six EGF repeat motifs, related to those present in the delta/notch/serrate 
family members, involve in cell adhesion (Laborda 2000). Previous studies 
suggested that DLKl plays a role in several differentiation processes such as 
adipogenesis and hematopoiesis (Li et al. 2005; Garces et al. 1999). It is notable that 
the tumor suppressor role of DLKl was proposed in renal cell carcinoma during the 
course of study (Kawakami et al. 2006). Therefore, I hypothesized that DLKl may 
also have an important role in NPC tumorigenesis, and its frequent silencing may 
confer advantages to tumor development. 
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Figure 4-18. Schematic diagram showing the location of the putative TSG locus 
mapping to 14q32. The TSG locus of about 1 Mb maps to 14q32.2-q32.31. This 
region flanks 3 BAC clones (bA123M6, bA94D19 and bA168L7), and the positions 
of the BAC clones were indicated by black solid bars. TSG, tumor suppressor gene. 
Table 4-5. Summary of the expression analysis of candidate genes within the 
TSG locus at 14q32.2-q32.31 in a panel of NPC cell lines and normal upper 
respira tory t ract tissues. The expression of the candidate genes was compared in 
five NPC cell lines, and the normal upper respiratory tract tissues including larynx 
and trachea, by semi-quantitative RT-PCR. Two down-regulated genes, MEG3 and 
DLKl, were highlighted in the table. DLKl was selected as a target gene for further 
studies 
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4.3.2 DLKl as a target of study at 14q32 
4.3,2 a Expression analysis of DLKl in normal human tissues and NPC cell lines 
DLKl contains five exons that encodes for a transmembrane protein (384 aa) 
containing six epidermal growth factor (EGF) repeat motifs closely related to those 
present in the delta/notch/serrate family of signalling molecule (Fig. 4-19A; Laborda 
2000). The tissue distribution of DLKl in a panel of normal adult and fetal human 
tissues was first examined by semi-quantitative RT-CR. In addition to high 
expression in larynx and trachea, DLKl mRNA expression was also highly detected 
in a number of adult tissues including kidney, breast, heart, pancreas, ovary and testis, 
but not in lung, colon and lymph node. Interestingly, DLKl was broadly expressed in 
embryonic tissues but not retained in adult lung and colon (Fig. 4-19B). On the other 
hand, DLKl was silenced or significantly under-expressed in a majority of NPC cell 
lines (4/5, Fig. 4-20B), but was highly expressed in the immortalized nasopharyngeal 
epithelial cell line NP69. 
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Figure 4-19A. Schematic transcript structure of DLKL DLKl contains five exons. 
The transcription start site was indicated by the curved arrow. The positions of the 
RT-PCR primers are indicated by black arrows. 
Figure 4-19B. Expression analysis of DLKl in normal tissues. DLKl was broadly 
expressed in all fetal tissues examined, but was only expressed in certain adult 
tissues, as determined by semi-quantitative RT-PCR. GAPDH was used as the 
internal control. 
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4.3,2b Methylation analysis ofDLKl in NPC 
As suggested previously, silencing of DLKl in renal cell carcinoma (RCC) 
may be attributed to gain of methylation at a DMR containing a CpG island (286bp) 
upstream of MEGS (Fig. 4-20A; Kawakami et al. 2006). Based on their findings, I 
sought to study whether such abnormality was also associated with DLKl silencing 
in NPC. Two pairs of MSP primers targeting either the methylated or umethylated 
allele were designed within this DMR. As revealed from MSP, this DMR was found 
to be hemimethylated in normal PBMC samples and hypermethylated in all NPC cell 
lines (Fig. 4-20B). Unexpectedly, no unmethylated allele was detected in DLKl-
expressing NPC cell line (HKl) , and only weak unmethylated allele was detected in 
NP69. This implies the presence of other more critical DMRs within the intergenic 
region in NPC. Nevertheless, this region seems to demonstrate gain of methylation in 
NPC cell lines, as shown from the fact that unmethylation was only weakly detected, 
when compared with the normal PBMCs. 
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Figure 4-20A. Schematic diagram of the DMR within the intergenic region of 
DLKl and MEGS, The white box indicates the location of the DMR (Genbank 
Accession Number ALl 17190, from 64,279 to 64,564), which is 1.67kb upstream of 
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MEG3. The MSP primers sites were indicated by black arrows. DMR, differential 
methylated region. 
Figure 4-20B. Expression analysis of DLKl in NPC cell lines and methylation 
analysis of the DMR. DLKl was significantly down-regulated in a majority of NPC 
cell lines, but was highly expressed in NP69, as determined by semi-quantitative RT-
PCR. GAPDH was used as the internal control. As revealed by MSP, the DMR was 
found to be hemimethylated in normal PBMCs (upper panel), but was 
hypermethylated in all NPC cell lines (lower panel). M, methylated; U, unmethylated. 
Figure 4-20C. Reactivation of DLKl expression after pharmacological 
demethylation. DLKl expression was significantly reactivated in NPC cell lines 
treated with 5-Aza-CdR alone or along with TSA, as determined by semi-
quantitative RT-PCR (upper panel). Concomitant increase in unmethylation of the 
DMR after drug treatment was also detected by MSP (lower panel). 
Figure 4-20D. Confirmation of the MSP products by direct sequencing. Both M 
and U MSP products were directly sequenced and confirmed. Methylated cytosine (C) 
would not be converted to uracil (T) and remained as C. The top panel shows the 
wild-type sequence (WT) without bisulfite conversion. The bottom panel shows the 
partial chromatogram of the sequence of the MSP products (M and U). 
4.3.2 c Restoration of DLKl expression after pharmacologic demethylation 
To test whether demethylation could restore expression of DLKl in NPC, two 
NPC cell lines (C666-1 and HKl) lacking DLKl expression were treated with 
demethylating agent 5-Aza-CdR or in combination with HDAC inhibitor TSA. 
Expression of DLKl was dramatically reactivated after treatment with 5-Aza-CdR, 
and the reactivation of its expression was more enhanced after treatment with 5-Aza-
CdR along with TSA (Fig. 4-20C). Concomitantly, an increase in unmethylated 
allele was also observed, as revealed by MSP. Taken together, these results suggest, 
for the first time, that silencing of DLKl is directly governed by aberrant epigenetic 
mechanisms including DNA methylation in NPC. 
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4,3,2d Functional study ofDLKl in NPC 
The frequent down-regulation of DLKl in NPC cell lines prompted us with 
the idea that DLKl is a functional TSG in NPC. To evaluate whether DLKl 
possesses a tumor suppressor role in NPC, I examined the inhibitory effect of DLKl 
on the proliferation of NPC cells by monolayer colony formation and soft agar assays. 
A mammalian expression vector containing the full-length DLKl cDNA (gift from 
Dr Keisei Okamoto) was transfected into two NPC cell lines lacking DLKl 
expression (CNEl and HNEl), and the number of surviving colony was scored after 
1-2 weeks G418 selection. A significant reduction in colony numbers was observed 
in both NPC cell lines transfected with the pcDNA3.1/DLKl expression vector, in 
comparison with the empty vector transfectants (/7<0.001; Fig. 4-21A and 4-2IC). 
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Figure 4-21 A. Effect of ectopic expression of DLKl on the clonogenicity of NPC 
cells. CNEl and HNEl cells were transfected with pcDNA3.1/DLKl or empty-
vector, and selected with G418. Inhibition of colony formation in monolayer culture 
was observed in tumor cells transfected with pcDNA3.1/DLKl, comparable to the 
empty-vector control. 
Figure 4-22B. Post-transfection expression analysis of DLKl. Total RNA was 
extracted from transfected cells and treated with DNase. RT-PCR was then 
performed to assess the expression DLKl in tumor cells transfected with empty-
vector or pcDNA3.1/DLKl. DLKl expression was only detected in cells transfected 
with pcDNA3.1/DLKl, but not in the empty vector control. 
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Figure 4-22C. Quantitative analyses of colony numbers. The numbers of colony 
were scored after selection. The numbers of colony in each empty vector-transfected 
cell line were set to 100%. Values are the mean 士 s.e. of triplicate experiments, p 
values were calculated using student's t-test. The two asterisks indicate statistical 
significant difference (/?<0.01). 
On the other hand, soft agar assay revealed that ectopic expression of DLKl 
could significantly inhibit the clonogenicity as well as the size of CNEl cells in soft 
agar (Fig. 4-23A and Fig. 4-23B). These in vitro data suggest that DLKl can 
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Figure 4-23A. Effect of ectopic DLKl expression on anchorage-independent 
growth of NPC cells. CNEl cells were transfected with pcDNA3.1/DLKl or empty-
vector, and selected with G418 for about 2 weeks in soft agar. Significant reduction 
in the number and size of colony was observed in tumor cells transfected with 
pcDNA3.1/DLKl, when compared with the empty-vector control. 
Figure 4-23B. Quantitative analyses of colony numbers in soft agar culture. 
Numbers of colony formed in soft agar culture were scored. The numbers of colony 
in the control was set to 100%. Values are the mean 士 s.e. of triplicate experiments, p 
values were calculated using student's t-test. The two asterisks indicate statistical 
significant difference (p<0.01). 
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4.3.2e Discussion 
Another part of the present project was to identify novel candidate TSGs for 
NPC at a putative TSG locus of about 1Mb mapping to chromosome 14q32.2-q32.1, 
which was found to show frequent copy number loss from our array-CGH data 
(unpublished data). Indeed, chromosome 14q32 has long been reported as a ‘hotspot, 
for chromosomal abnormalities in multiple human cancers, which is indicative of 
existence of a TSG(s). These findings prompted us to identify novel TSG(s) at this 
critical region in NPC. Expression profiling of the candidate genes residing in the 
critical region revealed that DLKl and MEGS were frequently down-regulated in the 
NPC cell lines examined, when compared with the normal larynx and trachea. The 
down-regulation indicates that these two genes may confer functional significance to 
NPC pathogenesis. In this study, DLKl was selected as the target for further 
functional studies. 
DLKl is a paternally imprinted gene, which encodes for a transmembrane 
protein containing a signal peptide followed by six epidermal growth factor-like 
repeat domains, a transmembrane domain, and a short intracellular tail at the C-
terminal. It is also a member of the epidermal growth factor-like proteins 
homologous to Notch/Delta/Serrate (Laborda 2000). Previous studies have 
demonstrated that DLKl is broadly expressed in a variety of murine and human fetal 
cells, but only present in a limited number of adult tissues (Tomehave et al. 1996; 
Floridon et al. 2000). Consistent with the previous expression analysis, our semi-
quantitative expression analysis also revealed that DLKl was highly expressed in all 
fetal tissues, but only retained in certain adult tissues (Fig. 4-19B), suggesting that 
DLKl expression may somehow be regulated during development. On the other hand, 
I found that DLKl was under-expressed in a majority of NPC cell lines but expressed 
at high level in the upper respiratory tract tissues and immortalized nasopharyngeal 
epithelial cell line NP69, showing that DLKl inactivation is common in NPC. 
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Together with the downstream maternal imprinted gene, MEGS, it has been 
proposed that the gene pair DLK1/MEG3 forms an imprinted domain similar to that 
of IGF2/H19, because there are a number of structural and epigenetic similarities 
shared between the IGF2/H19 and the DLKl/MEG 3 domains. For instance, 
DLK1/MEG3 and IGF2/H19 are both reciprocally imprinted gene pair, and 
paternally methylated differential methylated regions (DMR) associated with both 
genes have been implicated in the regulation of their imprinting (Takada et al. 2002; 
Wylie et al. 2000). However, the mechanism of regulation of the DLK1/MEG3 gene 
pair is proposed to be more complex than IGF2/HI9 (Lin et al. 2003). Although 
deregulation of DLKl expression has been frequently reported in multiple human 
tumors, no consensus mechanism has yet been found for the deregulation of DLKl 
expression. A number of intergenic-DMR (IG-DMR) have been assigned within the 
DLKJ/MEG3 imprinted domain (Paulsen et al. 2001; Wylie et al. 2000). But 
discrepancies have been observed in recent studies that dysregulation of DLKl 
expression may not be attributed to aberrant methylation of those previously reported 
DMRs. For instance, a recent study demonstrated that hypermethylation at a DMR 
upstream of MEG3 results in abnormal silencing of DLKl in RCC (Kawakami et al. 
2006), but this DMR was neither an IG-DMR nor a CTCF-binding site reported 
previously. Based on their findings, I sought to investigate whether such abnormality 
is also associated with DLKl silencing in NPC. As revealed by MSP, this DMR was 
found to be hypermethylated in all NPC cell lines but was hemimethylated in normal 
PBMC samples (Fig. 4-20B and 4-20C); this finding is consistent with observed in 
RCCs (Kawakami et al. 2006). However, this DMR was also found to be 
hypermethylated in DL/C/-expressing cell line, indicating that there may be other 
even more critical regions residing within the intergenic region in NPC. Moreover, 
expression of DLKl was significantly reactivated after treatment with demethylating 
agent, 5-Aza-CdR, in NPC cell lines, suggesting that DLKl silencing is directly 
mediated by DNA methylation, and is associated with gain of methylation in the 
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region upstream of MEGS. Nonetheless, we cannot rule out the possibility that 
aberrant methylation of other critical regulatory regions may also contribute to the 
deregulation of DLKl in NPC, so further studies are needed to elucidate the precise 
regulatory mechanism. 
A number of functions have been ascribed to DLKl , including roles in 
adipogenesis (Garces et al. 1999), hematopoiesis (Li et al. 2005; Kaneta et al. 2000), 
Notch 1 signalling (Baladron et al. 2005), adrenal gland development (Gaetano et al. 
1992) and wound healing (Samulewicz et al. 2002). However, the functional 
significance of DLKl in carcinogenesis has not yet been clearly known and it appears 
that the function of DLKl varies in different types of cancer. Oncogenic activities of 
DLKl have been suggested in glioblastoma mutliforme (GBM) in which DLKl was 
over-expressed, and it was demonstrated that DLKl could promote cell proliferation 
of GBM cell lines (Yin et al. 2006). Increased expression of proliferation-enhancing 
protein such as cyclin Dl , CDK2, and E2F4 was concomitantly observed in DLKl-
expressing GBM cells. A recent report also added lines of evidence for the oncogenic 
role of DLKl in HCC, in which up-regulation of DLKl was observed. In that study, 
the ability of exogenous expression of DLKl in promoting proliferation of HCC cell 
lines was demonstrated. Significant suppression of cell proliferation and 
tumorigenicity was also observed in a panel of HCC cells where DLKl was silenced 
by siRNA (Huang et al. 2006). In contrast to its oncogenic role, DLKl has been 
suggested as a putative TSG in RCCs in which down-regulation of DLKl was found 
to be associated with gain of methylation at a DMR upstream of MEGS. More 
importantly, they provided in vivo functional evidence that DLKl can significantly 
reduced tumor size using the mice model (Kawakami et al. 2006). 
Despite the fact that the function of DLKl in carcinogenesis seems to 
dichotomize into promoting and inhibiting tumor growth, the results from the 
functional study of the present project support the view that DLKl may function as a 
TSG in NPC. The function of DLKl is likely to be dependent of tumor type. 
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Interestingly, previous yeast-two-hybrid system revealed that DLKl interacts with a 
growth-arrest specific protein 1 (GASl), which is a putative tumor suppressor 
(Baladron et al. 2002). Besides, it is noteworthy to mention that DLKl was proposed 
to function as a negative regulator of Notch 1 through competing for ligand binding; 
it has been demonstrated that inhibition of Notch 1 signalling by DLKl may in turn 
regulate the expression of Hes-1 and possibly other targets activated by Notch 1 
(Baladron et al. 2005). In fact, Notch signalling plays a critical role in maintaining 
the balance among cell proliferation, differentiation and apoptosis. Notch can 
variously promote or limit tumor growth, depending on the tumor type. It is 
suggested that Notch may contribute to tumorigenesis by inhibiting differentiation, 
promoting survival or accelerating proliferation. A number of potential oncogenic 
targets of Notch-1 has been suggested, such as cyclin Dl , AKT, ERBB2 and P-
catenin (Roy et al. 2007; Miele 2006). The clearest example to illustrate oncogenic 
Notch 1 signalling comes from T-acute lymphoblastic leukaemia/lymphoma (T-ALL). 
Activating mutations of Notch-1 are present in about 50% of T-ALL, making Notch 1 
the most commonly activated oncogene in this cancer (Grabber et al. 2006). To date, 
cell autonomous gain-of-function mutations in Notch receptors have not yet been 
found in solid tumors including NPC, it is suggested that Notch signalling may exert 
its oncogenic effects through ligand-mediated activation (Roy et al. 2007). It is likely 
that epigenetic inactivation of DLKl, which is a negative regulator of Notch-1, 
promotes cell proliferation and progression of NPC cells through reactivation of 
Notch I signalling. Whether such scenario exists in NPC is an open question, because 
the role of oncogenic Notch 1 signalling has not yet been studied in this cancer. But 
the data presented here will facilitate the elucidation of molecular pathogenesis of 
NPC, and provide important insight into the potential participation of Notch 
signalling in NPC oncogenesis. 
In summary, this is the first report to show that DLKl was frequently down-
regulated in NPC cell lines at transcriptional level. The methylation analysis also 
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suggested that its silencing is associated with aberrant DNA methylation, and is 
correlated with the gain of methylation at a region upstream of MEGS, However, the 
precise mechanism as well as the critical regulatory regions governing the frequent 
silencing of DLKl in NPC warrants further investigation. In addition, the functional 
study demonstrated that ectopic expression of DLKl strongly inhibited the in vitro 
growth of NPC cells, giving support for the candidacy of DLKl as a functional TSG 
in NPC. Collectively, my data suggest that DLKl may be a critical candidate TSG at 
chromosome 14q32, and is frequently inactivated by epigenetic abnormalities in 
NPC. It is of paramount importance to carry out further studies to elucidate the 
functional role of DLKl and its regulation so as to better understand the pathogenesis 
o f N P C . 
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Chapter 5 General discussion 
Cancer genome is characterized by multiple non-random chromosomal gains 
and losses. These hallmark features of cancer represent a promising avenue to guide 
searches for tumor suppressor genes (TSGs) and oncogenes, of which dysregulation 
directly contributes to carcinogenesis. Undoubtedly, identification of all critical 
TSGs as well as oncogenes is crucial to the elucidation of cancer molecular 
pathogenesis. In particular, loci demonstrating frequent losses can flag regions likely 
to harbor TSGs. Therefore, the typical strategy to search for novel TSGs often first 
begins with the identification of a chromosomal region that demonstrates frequent 
copy number loss or LOH in a specific type of cancer; and then hunt for the 
frequently inactivated gene within the region, followed by elucidation of the mode of 
inactivation as well as its tumour suppressor role in that cancer type (Balmain 2002; 
Presneau et al. 2003). But the search for the genetic alterations leading to silencing of 
genes within the critical regions is laborious and sometimes may not be feasible, due 
to the fact that cancer is more resourceful than we once thought in terms of the ways 
cancer cells adopt to silence those genes that impede rapid cell growth. That is, as 
reviewed extensively in Chapter 1, TSGs can be inactivated through epigenetic 
mechanisms, either on both alleles, or on just one when the other has been deleted or 
mutated. Notably, there is also compelling evidence that a strong TSG candidate(s) 
within a region of interest need not be mutated or homozygously deleted but is often 
silenced by promoter methylation. It is anticipated that many more epigenetically 
silenced Class II TSGs will soon be disclosed (Dammann et al. 2000; Sager 1997). 
Nonetheless, characterization of the frequently deleted regions remains useful to 
guide searches for TSGs, as one can take epigenetic silencing into account during the 
elucidation of critical genes within the region of interest. 
Instead of using genome-wide screening of differentially methylated regions 
between normal and tumour cells to identify epigenetically silenced TSGs, I adopted 
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a genomic approach coupled with epigenetic analysis to identify novel TSGs that are 
frequently silenced by aberrant DNA methylation within the two putative TSG loci. 
The current approach allows more candidate genes to be disclosed, including those 
that are not inactivated epigenetically, while the discovery of candidate genes by the 
former one is only limited to those silenced by methylation. In this project, a 3040-
BAC clone based CGH-array (Sanger Institute whole-genome array) with a 
resolution of � 1 M b was performed previously to detect genome-wide DNA copy 
number abnormalities in NPC (unpublished data). In fact, high-resolution aCGH has 
markedly facilitated TSG identification by providing more TSG loci in a more 
precise manner, and provides many advantages over conventional CGH and other 
conventional cytogenetic methods for reliably detecting and precisely mapping 
chromosomal changes (Pinkel et al. 1998; Pinkel and Albertson 2005). Among a 
series of deletions and amplifications detected from the aCGH, chromosome region 
5ql l -q l2 and 14q32.2-q32.31, which demonstrate frequent copy number loss, were 
selected as target regions for the identification of novel TSGs in my study. In accord 
with our findings, these two regions were also found to demonstrate frequent copy 
number abnormalities in a wide range of cancers from previous studies, giving 
further support for the presence of TSG(s) within these regions. Up to date, 5ql l -q l2 
is completely devoid of reports for the presence of TSG(s) in any types of cancer 
including NPC. On the other hand, although two candidate genes {DLKl and MEGS) 
at 14q32 have been recently proposed as candidate TSGs in certain types of cancer 
(Zhang et al. 2003; Kawakami et al. 2006), the presence of TSGs at 14q32 has not 
yet been dated in NPC. Therefore, I sought to disclose novel TSGs within these two 
critical regions using NPC as the cancer model. By comparing the expression level of 
the candidate genes within the two critical regions in NPC cell lines and normal 
upper respiratory tract tissues, a number of down-regulated genes were identified, 
and three candidates from which were selected as the targets for further expression 
analysis in other carcinomas and functional study. MGC80 and TUSC14, mapping to 
93 
5ql2, were identified as candidate TSGs in multiple carcinomas, whereas DLKl at 
14q32 was identified as a candidate TSG in NPC. My study also provided solid 
evidence to show that silencing of the candidate genes is mainly associated with 
aberrant DNA methylation, through studying the methylation status of the candidate 
genes in a large collection of multiple carcinoma cell lines. The data from my study 
not only provide new members to the current list of candidate TSGs, but also gives 
support for the validity of the approach adopted here. 
A number of potential roles of the candidate TSGs in tumorigenesis are 
suggested in Chapter 4, which provide new insights into the understanding of the 
molecular pathogenesis of cancer. As revealed from the in vitro functional analysis, 
MGC80 and TUSC14 residing in 5ql2 were found to be functional TSGs in multiple 
carcinomas. Indeed, our current knowledge is completely lack of information for 
their roles in tumorigenesis. As discussed in Chapter 4, MGC80 may act to suppress 
tumor growth through protein ubiquitination, as the RING-finger domain has been 
proposed as a critical module of the protein ubiquitin ligase E3s (Fang et al. 2003), 
and abrogation of tumor suppressor ability by disrupting this module has been 
demonstrated in a number of RING-fmger domain-containing tumor suppressors, 
pinpointing the critical role of this domain in carcinogenesis. As a potential binding 
protein of the RGS proteins, TUSC14 may be involved in intracellular trafficking of 
the RGS proteins. Inactivation of TUSC14 may thus lead to aberrant G-protein 
signallings, which in turn drive oncogenesis. Besides, the paternal imprinted DLKl at 
14q32 was also identified as a candidate TSG for NPC in my study. Suggested as a 
negative regulator of Notch 1 signalling (Baladron et al. 2005), DLKl may act to 
suppress tumorigenesis by inhibiting the oncogenic Notch 1 signalling in NPC, 
although the participation of Notch signallings has not been addressed in NPC. It is 
noteworthy that the suggested potential participations of these candidate TSGs have 
not been extensively investigated, particularly the roles of the two completely novel 
candidates at 5ql2. Cancer is by no means a single-step disease but, instead, is a 
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multi-step and complex disorder. Despite the fact that a number of cellular pathways 
are known to be directly or indirectly involved in carcinogenesis, it is believed that 
many unknown areas are stilling waiting for exploration. The data presented in my 
study may facilitate the study on those 'untouched areas' in carcinogenesis. It is 
likely that a better understanding of the cancer molecular pathogenesis will soon be 
obtained with these unknown areas are being elucidated extensively. 
Intriguingly, the two down-regulated candidate TSGs, MGC80 and TUSCJ4, 
identified from the TSG locus at 5ql l -q l2 are both residing in 5ql2. When 
analysing the methylation status of these two genes, it was surprised that their 
methylation patterns correlated with each other pretty well in various carcinoma cell 
lines, such as in NPC, breast, gastric and lung carcinoma. These interesting data 
suggest that there may be a broad domain of epigenetic silencing across the 
chromosome band 5ql2, leading to a broad band of epigenetic silencing {MGC80 
and TUSCJ4) in multiple carcinomas. The co-methylation of neighbouring genes 
suggests that the adjacent position of the genes plays a role in the mechanism of 
methylation. One possibility is that co-methylation results from regional spreading of 
methylation to neighbouring genes (Smith and Costello 2006). 
Notably, a recent study has given solid evidence to challenge the dogma that 
epigenetic changes in cancer are solely focal events by identifying a broad domain of 
epigenetic silencing at chromosome band 2ql4.2 in colorectal cancer (Frigola et al. 
2006). In the study, they identified a small fragment of 4-Mb mapping to 2ql4.2 that 
was commonly hypermethylated in colorectal cancer. There was an overall 
suppression of expression of the ten genes across the 2ql4.2 band, even in the genes 
that remained unmethylated. They also found that dimethylation of H3K9 uniformly 
blanketed every region tested in the 2ql4.2 band, regardless of the DNA methylation 
status of individual gene in tumours. These data suggest a coordinate suppression of 
gene expression across the entire 2ql4.2 band, which is mediated by seeds of 
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aberrant DNA methylation and uniform histone modifications (Smith and Costello 
2006). Nevertheless, whether this model can also be applied to the 5ql2 band 
remains elusive and it is also unclear whether this broad range of epigenetic silencing 
exists in primary tumours or not, because the methylation status of these 
neighbouring genes has not been addressed in primary tumours and other CpG 
islands within this chromosome band have not been investigated. But this region 
definitely worths further investigations, as it may have implications for the discovery 
of epigenetic markers, as well as defining potential targets for epigenetic therapy. 
Furthermore, as shown from the methylation analysis, the three candidate 
TSGs were found to be frequently inactivated by methylation in multiple carcinomas, 
and hypermethylation of these genes appears to be tumour-specific, although their 
methylation status has not yet been dated in primary tumours. With these 
characteristics, the candidate TSGs identified in my study can potentially be 
developed as non-invasive tumour markers for cancer diagnosis and risk assessment. 
Indeed, one major reason for causing high mortality rate of cancer is lack of effective 
diagnostic agents. As reviewed in Chapter 1, extensive effort has been made recently 
on the potential use of detection for hypermethylation of TSGs in clinical diagnosis 
of a number of human cancers, as this molecular diagnosis is rapid and non-invasive. 
Detection of promoter CpG island hypermethylation offers several advantages over 
the use of other DNA alterations in cancer. Abnormal DNA methylation represents a 
chemically and biologically stable tumour-specific marker that can be readily 
detected. Once a tumour cell has acquired methylation of a specific gene, this 
specific methylation pattern will stably be transmitted and is often enhanced during 
cancer progression (Markl et al. 2001). In contrast to point mutations, which variably 
occur within a TSG, DNA methylation occurs mainly at CpG islands in the promoter 
regions of TSGs. Therefore, a set of MSP primers may be enough for detecting the 
presence of methylation, whereas the detection of point mutation requires the use of 
many primers sets, and is far more laborious and tedious. Moreover, as compared 
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with other frequent chromosome changes in cancer, such as LOH, CpG island 
hypermethylation constitutes a positively detected signal, as opposed to a loss of 
signal in LOH analysis (Widschwendter and Jones 2002). Besides, detection of 
methylation of a single gene in a specific type of cancer is by no means 
representative, effective cancer diagnosis necessitates the establishment of a panel of 
representative genes that are specifically methylated in a specific type of cancer. 
Unquestionably, identifying more epigenetically silenced TSGs in different types of 
cancer will provide more choices for the design of a reasonably sized marker panel to 
provide indices for monitoring cancer risk assessment, early diagnosis, and cancer 
prognosis. 
It is also worth mention that methylation is sometimes associated with ageing 
in the normal epithelium. Age-related methylation is found to be more prevalent in 
normal-appearing epithelium from cancer patients compared with normal epithelium 
from controls (Issa et al. 2001). In this way, methylation changes might indicate a 
risk for cancer rather than show the presence of cancer. Before DNA methylation can 
broadly be used for early detection, it is of concern to show which DNA methylation 
patterns in normal tissues are associated with carcinogenesis and which DNA 
methylation patterns are associated with age but do not predispose to cancer in 
general (Widschwendter and Jones 2002). 
Aside from being developed as biomarkers, the three epigenetically silenced 
candidate TSGs identified may also provide important insights to the development of 
an entirely new therapeutic approach in which the goal is to reverse gene silencing. 
Unlike genetic alterations such as deletion and mutations, epigenetic modifications 
are reversible. This feature makes the epigenetically silenced TSGs an attractive 
target for cancer therapy. My study demonstrated that the expression of the three 
candidate TSGs was robustly reactivated in tumor cells, after treatment with the 
demethylating drug, 5-Aza-CdR, although the drug concentration used was higher 
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than that in clinical settings. As reviewed in Chapter 1, treatment with demethylating 
agent can restore the activities of dormant genes such as pi 6 and decrease the growth 
rate of cancer cells in a heritable fashion. As a DNMTs inhibitor, 5-Aza-CR has been 
recently approved by the United States FDA for the treatment of myelodysplastic 
syndrome (MDS), and its derivative, 5-Aza-CdR, is now in Phase III study. Although 
the use of these nucleoside analogues has been widely studied in the treatment of 
haematological diseases such as MDS, their therapeutic values remains to be seen in 
other solid cancers such as NPC. 
One major obstacle to the use of epigenetic drugs is that they are non-specific 
and may reactivate genes non-discriminately. However, this may not be an 
insurmountable problem, because the DNMTs inhibitors only act on dividing cells, 
rendering non-dividing normal cells unaffected. Also, it appears that the drugs 
preferentially activate genes that have become abnormally silenced in cancer (Liang 
et al. 2002). Although the reason for this is still obscure, it is suggested that the 
chromatin structure associated with a pathologically silenced gene may be more 
susceptible to reactivation than the highly compacted chromatin state induced by 
normal cellular settings (Jones and Baylin 2007). 
Nonetheless, the epigenetically silenced TSGs still represent a promising 
avenue for the development of new cancer therapy, as these genes remain intact 
within the genome. Therefore, it will be of paramount importance to develop a 
specific targeted therapy in which the ultimate goal is to specifically reactivate a set 
of genes (TSGs) that are critical to the growth suppression of a specific type of 
cancer. In this regard, the candidate TSGs identified in my study may act as potential 
targets for the development and design of such therapy. 
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Chapter 6 Summary 
Carcinogenesis is by no means a single-step process but instead, is a multi-
factorial and complex process, which involves a series of genetic alterations 
including aberrant activation of proto-oncogenes and/or the inactivation of TSGs. 
However, the process of carcinogenesis is far beyond from fully understood, as there 
are still many cancer-related genes such as TSGs waiting to be discovered. 
Chromosome loci demonstrating frequent losses can act as a tag for the presence of 
TSGs. A high-resolution array-CGH was performed previously to detect genetic 
copy number abnormalities genome-wide in NPC, and from which 5ql l -q l2 and 
14q32.2-q32.31 were selected as the target regions for the identification of novel 
candidate TSGs in my study. In addition, aside from genetic abnormalities, 
epigenetic aberrations such as DNA methylation have been recognized as a common 
mechanism for the inactivation of TSGs in virtually all types of human malignancy, 
and it is evident that a strong TSG candidate(s) within a region of interest need not 
be mutated but is often silenced by promoter methylation. Therefore, the objective of 
the current project was to identify novel epigenetically silenced candidate TSGs 
residing in 5ql l -q l2 and 14q32.2-q32.31 in multiple carcinomas by using an 
integrative genomic and epigenetic approach. 
The expression of the candidate genes residing in two critical regions of 10-
Mb and 1-Mb mapping to 5ql l -q l2 and 14q32.2-q32.31, respectively, was first 
compared in a panel of NPC cell lines and normal upper respiratory tract tissues. 
Among a number of down-regulated genes identified, three candidate genes {MGC80 
and TUSC14 at 5ql2 and DLKl at 14q32) were selected for further analysis. Though 
a series of methylation analysis, I have provided evidence for the first time that the 
frequent silencing of MGC80 and TUSC14 in multiple carcinomas was mainly 
attributed to aberrant DNA methylation. Further functional study demonstrated that 
ectopic expression of MGC80 and TUSC14 in carcinoma cells lacking the expression 
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could strongly inhibit anchorage-dependent and independent growth of multiple 
tumor cells in vitro, giving support for the candidacy of MGC80 and TUSC 14 as 
functional TSGs. Also, by the same token, the paternal imprinted gene DLKl at 
14q32 was identified as a candidate TSG frequently silenced by methylation for NPC. 
In conclusion, three novel epigenetically silenced candidate TSGs, MGC80, 
TUSC 14 and DLKl, were identified in my study. My findings provide important 
insights to the understanding of the molecular pathogenesis of cancer. The 
epigenetically silenced TSGs identified in my study may represent a promising 
avenue for the development of non-invasive epigenetic biomarkers for molecular 
diagnosis and prognostics, and therapeutic targets for cancer therapy. 
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Chapter 7 Future study 
In this study, a number of candidate genes were proposed as novel 
epigenetically silenced candidate TSGs, but there are some aspects remain to be 
explored. 
1) Study of genetic inactivation leading to gene silencing 
The present study demonstrated high frequency of epigenetic silencing of the 
identified candidate TSGs in multiple tumors, suggesting that genetic alterations are 
likely to play a less important role in gene silencing in tumors. Indeed, genetic 
abnormalities such as mutation and deletion can act as one or both of the causes for 
TSG inactivation, according to the Knudson's two-hit hypothesis. Even though the 
concept that epigenetic silencing is more common than genetic alterations in TSG 
silencing is now emerging, we cannot rule out the participation of genetic alterations 
in silencing of the candidate TSGs, as they were actually identified from the 
chromosome loci that demonstrate copy number loss. The issue of deletion was not 
extensively investigated. It is possible that deletion (one allele) may operate in 
concert with DNA methylation (another allele) to silence the gene. Although deletion 
and mutation analysis is far more laborious, this will definitely provide a more 
complete picture concerning the mechanism for the inactivation of these TSGs in 
multiple tumors. 
2) Fur ther methylation analysis 
The methylation analysis of the current study was only limited to tumor cell 
lines. Although a good correlation between methylation status and expression was 
demonstrated for the candidate TSGs, it is unclear whether such correlation exits in 
primary tumors. In order to make the present data more representative and provide 
fruitful insights into the potential use of the candidate TSGs as epigenetic markers 
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for cancer diagnosis, the methylation status of the candidate genes should be 
addressed in primary tumors such as NPC. 
On the other hand, the methylation study concerning DLKl silencing was 
merely based on the previous study about DLKl silencing in renal cell carcinoma. 
Indeed, the regulatory mechanism of the DLK1/MEG3 imprinted domain is proposed 
to be a complex one, it is likely that other regions (IG-DMR) within the imprinted 
domain also play a role in regulating the DLKl expression. Therefore, it is of interest 
to study the methylation status of other IG-DMR so as to facilitate our understanding 
of the precise mechanism involved in DLKl regulation, as well as the role of 
abnormal genomic imprinting in carcinogenesis. 
3) Further functional characterization of the candidate TSGs 
In this study, the three candidate genes were proposed to act as novel 
functional TSGs in various carcinomas. These conclusions are drawn from their 
frequent down-regulation in multiple tumors, tumor-specific methylation, and in 
vitro tumor suppressor function analyses. Indeed, the normal physiological role and 
the functional consequence of inactivation of these candidate genes, such as MGC80 
and TUSC14, remain elusive. For instance, in vivo studies involving the use of mice 
models will provide more solid evidence to define the tumor suppressor function of 
the candidate gene, and further in vitro studies such as the characterization of 
interacting protein partners will give important clues to the potential participation of 
the candidate gene in existing cellular pathways. Extensive exploration of the roles of 
these candidate TSGs in normal and neoplastic settings will definitely provide a 
better understanding of carcinogenesis. 
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